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The incidence of premature birth is rising in Southern Africa. Premature birth is associated 
with, among other, human immunodeficiency virus (HIV)-infection during pregnancy. 
Women with HIV, chronic malnutrition and obesity are more likely to give birth to 
premature infants with intra-uterine growth restriction (IUGR). Providing the HIV-exposed 
premature infant with breastmilk accompanied by maternal and infantile anti-retroviral 
therapy (ART) are key strategies to reduce HIV mother-to-child-transmission (MTCT), and 
infant morbidity and - mortality. Recent literature showed a difference in the breastmilk 
composition of HIV-infected and HIV-uninfected mothers. The effects of HIV infection and 
ART on the breastmilk composition of mothers of premature infants are, however, largely 
unknown. 
Aims and Objectives 
The main aim of the study was to assess and compare the breastmilk composition of HIV-
infected mothers receiving ART and HIV-uninfected mothers who gave birth to premature 
infants. Secondary objectives of the study were to assess the maternal nutritional status of 
HIV-infected and HIV-uninfected mothers as well as to assess the neonatal nutritional status 
of premature infants in relation to maternal nutritional status, HIV status and ART regimen. 
Participants and Methods 
The study was designed as a cross-sectional, descriptive study with an analytical 
component. Study participants included HIV-infected and HIV-uninfected mothers who gave 
birth to premature infants. The women were subdivided into four groups according to HIV-
status and the length of gestation. Mothers provided demographic information and two 
breastmilk samples on day seven and nine of lactation. Maternal anthropometric data 
[weight, height and mid-upper arm circumference (MUAC)] were collected on day seven 
postpartum. Infant anthropometric data [weight, length and head circumference (HC)] were 
obtained at birth and length and HC data were obtained once more on day seven 
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postpartum. Breastmilk samples were analysed for energy, protein, carbohydrates, fat, 
phosphate, iron, zinc and copper. 
Results 
The study population consisted of 38 HIV-infected women receiving ART and 36 HIV-
uninfected women who gave birth to premature infants. Protein (1.95 vs. 1.78 g/100g; 
p=0.04), fat (4.42 vs. 3.49 g/100g; p=0.01) and copper (0.64 vs. 0.56 mg/l; p=0.02) in 
breastmilk samples were higher while carbohydrate (5.37 vs. 6.67 g/100g; p=0.002) and zinc 
(5.26 vs. 5.78 mg/l; p=0.04) were lower in HIV-infected women compared to HIV-uninfected 
women. Zinc levels were significantly lower in HIV-infected women with early gestation 
infants, with lowest levels in women who received ≤4 weeks ART (0.58mg/l; p=0.03). Total 
energy (78.22 vs. 61.48 kCal/100ml) and fat (5.39 vs. 3.00g/100ml) levels were significantly 
higher in late gestational HIV-infected women who received <4 weeks ART. Copper levels 
(0.61mg/l) were higher in late gestation women who received 4-20 weeks ART exposure 
(p=0.05). The variances in nutritive values in these milk samples did not, however, range 
outside the normal values of premature breastmilk composition. 
The mean maternal BMI was 26.7kg/m2 and MUAC was 289mm. Maternal undernutrition 
(9%) and obesity prevalence (9%) was low. There was a high prevalence of IUGR (54%). 
Neither maternal nutritional status (p=0.79) nor HIV-status and ART regimen (p=0.72) were 
associated with IUGR. Similarly, the nature of IUGR (symmetrical vs asymmetrical) was not 
associated with maternal HIV-status (p=1.00). Head circumference restriction was less 
prevalent in infants born to women with ART exposure >20 weeks (p=0.003).  
Conclusion  
HIV-infected women on ART can safely breastfeed their premature infants.  Maternal 
nutritional status, HIV-status and ART regime did not influence neonatal nutritional status 
among premature infants in this study. Maternal ART over a longer period may protect the 
baby against IUGR, with specific reference to head circumference. 






Die voorkoms van premature geboortes is aan die toeneem in Suider Afrika. Daar is ‘n 
beduidende verwantskap tussen premature geboorte en menslike immuniteitsgebreksvirus 
(MIV)-infeksie tydens swangerskap. Moeders met MIV of moeders wat chronies wangevoed 
is of vetsugtig is, is meer geneig om geboorte aan ’n premature baba met intra-uteriene 
groeivertraging (IUGV) te skenk. Twee belangrike strategieë om MIV-oordrag van moeder na 
kind te voorkom asook om morbiditeit en mortaliteit te verlaag is om premature babas met 
borsmelk te voed en terselfdertyd die moeder en baba van antiretrovirale terapie (ART) te 
voorsien. Onlangse literatuur rapporteer dat daar verskille in die borsmelksamestelling van 
MIV-geїnfekteerde en MIV-ongeїnfekteerde moeders is. Die uitwerking van MIV en ART op 
die borsmelksamestelling van die moeders van premature babas is egter tans onbekend.  
Studiedoelwitte 
Die primêre doel van die studie was om die borsmelksamestelling van moeders wat met 
MIV-geїnfekteer is en dié van moeders wat nie met MIV-geїnfekteer is nie, te bepaal en te 
vergelyk. Die sekondêre doelwitte was om die voedingstatus van MIV-geїnfekteerde en 
MIV-ongeїnfekteerde moeders te bepaal en te vergelyk, sowel as om die neonatale 
voedingstatus van premature babas te bepaal en in verhouding met maternale 
voedingstatus, MIV-status en ART-regime te evalueer. 
Deelnemers en Metodes 
Die studie-ontwerp was ’n beskrywende deursnit-studie met ’n analitiese komponent. 
Deelnemers het MIV-geїnfekteerde en MIV-ongeїnfekteerde moeders wat geboorte aan ŉ 
premature baba geskenk het, ingesluit. Moeders is verder in vier groepe volgens MIV-status, 
gestasietydperk en ART-tydperk verdeel. Moeders het demografiese inligting asook twee 
borsmelkmonsters op dag sewe en nege van laktasie verskaf. Maternale antropometrie 
(gewig, lengte en midarmomtrek) is op dag sewe postpartum geneem. Neonatale 
antropometrie (gewig, lengte en kopomtrek) is met geboorte geneem en lengte en 
Stellenbosch University  https://scholar.sun.ac.za
v 
 
kopomtrek is op dag sewe postpartum weer geneem. Die borsmelkmonsters is vir totale 
energie, proteїene, koolhidrate, vet, fosfaat, yster, sink en koper geanaliseer. 
Resultate 
Die studiepopulasie het uit 38 MIV-geїnfekteerde moeders wat ART ontvang en 36 MIV-
ongeїnfekteerde moeders met premature babas, bestaan. Die proteїene- (1.95 vs. 1.78 
g/100g; p=0.04), vet- (4.42 vs. 3.49 g/100g; p=0.01) en koperinhoud (0.64 vs. 0.56 mg/l; 
p=0.02) in die borsmelkmonsters was verhoog en die koolhidraat- (5.37 vs. 6.67 g/100g; 
p=0.002) en sinkinhoud (5.26 vs. 5.78 mg/l; p=0.04) was verlaag onder MIV-geїnfekteerde 
moeders vergeleke met dié van MIV-ongeїnfekteerde moeders. Sinkvlakke was beduidend 
laer onder MIV-geїnfekteerde moeders, met die laagste vlakke onder vroeë-gestasie 
moeders met ART blootstelling <4 weke (0.58mg/l; p=0.03). Die totale energie- (78.22 vs. 
61.48 kKal/100ml, p=0.03) en vetvlakke (5.39 vs. 3.00g/100ml, p=0.04) was beduidend hoër 
onder laat-gestasie MIV-geїnfekteerde moeders met <4 weke ART. Kopervlakke was hoër 
(0.8mg/100ml) onder die laat-gestasie MIV-geїnfekteerde moeders met 4-20 weke ART 
blootstelling (p=0.05).  
Die gemiddelde maternale LMI was 26.7 kg/m2 en die gemiddelde midarmomtrek was 289 
mm. Die voorkoms van maternale ondervoeding (9%) en vetsugtigheid (9%) was laag. Daar 
was ’n hoë voorkoms van IUGV (54%). Maternale voedingstatus (p=0.79), MIV-status en 
ART-regime (p=0.82) was nie geassosieer met IUGV nie. Net so was die tipe IUGV 
(simmetries teenoor onsimmetries) nie geassosieer met maternale MIV-status nie (p=1.00). 
Kopomtrekvertraging was beduidend laer onder babas van moeders met >20 weke ART 
blootstelling (p=0.003). 
Gevolgtrekking 
MIV-geїnfekteerde moeders kan veilig hul premature babas borsvoed. Maternale 
voedingstatus, MIV-status en ART regime het nie IUGV in premature babas in hierdie studie 
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BRIEF OUTLINE OF THE THESIS 
This thesis is devided into four chapters. The outline of each chapter is as follows: 
Chapter 1 covers the literature background of the investigation. 
Chapter 2 describes the methodology of the investigation. 
Chapter 3 presents the results of the investigation in two separate scientific articles. 
Article 1: Differences in Breastmilk Composition of HIV-infected and HIV-uninfected 
mothers of Premature Infants: Effects of Antiretroviral Therapy. 
Article 2: Anthropometric Parameters of HIV-Infected and HIV-Non Infected Mothers 
and their Premature Infants. 
Chapter 4 concludes the study objectives and findings. A set of null hypotheses are accepted 
or rejected. Limitations of the study are discussed and recommendations for further 

























A premature infant is defined as an infant born <37 weeks’ gestation.1 Fifteen million 
premature births occur worldwide of which 60% of these deliveries occur in low-and middle 
income countries.2 Premature delivery is considered a significant global perinatal health 
problem with a rising incidence in Southern Africa.  In 2010, the incidence of premature 
births was 17.5% compared to 6.2% and 10.6% in Europe and North America respectively.3 
In a meta-analysis by Beck and colleagues, the worldwide prevalence of premature births 
was found to be 9.6% with 85% of these preterm births concentrated in Africa and Asia.3  
Data from developing countries suggest that human immunodeficiency virus (HIV)-infected 
mothers have an increased risk of giving birth to premature infants and the occurrence is 
directly associated with clinical stage of disease.4-6 HIV-infected women were also found to 
be more likely to give birth to low birth weight (LBW) and growth restricted infants.4 A 
recent African study found the incidence of prematurity among HIV-infected mothers to be 
19.1% and the incidence of LBW infants to be 11.5%.7  
Premature infants have a substantially higher risk of dying and several short- and long-term 
complications due to immaturity of major organ systems.3,4 One of the key strategies to 
increase the survival rate of premature infants is to provide breastmilk early and exclusively. 
Breastmilk is the optimal feeding modality and is associated with lower rates of mortality 
and morbidity in the premature infant population. Furthermore, breastmilk provides the 
ideal nutritional, gastrointestinal and immunological components and is associated with 
psychological and developmental advantages in premature infants.8 Recent South African 
(SA) data showed that there were differences in certain compositional factors of HIV-
infected and HIV-uninfected women who had given birth to term-9 and preterm infants.10    
1.2 INTERVENTIONS THAT PROVIDE PROTECTION AGAINST MOTHER TO CHILD 
TRANSMISSION OF HUMAN IMMUNODEFICIENCT VIRUS  
Data from 2008 indicated that 10.9% of South Africans over the age of two years lived with 
HIV infection11 and one in three SA mothers who attended antenatal clinics was HIV-
infected.12  
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Given the seriousness of the SA HIV epidemic, concerns have been raised regarding the 
vertical transmission of HIV through breastmilk.13 In the past SA guidelines provided HIV-
infected mothers with the option of either breastfeeding exclusively or providing formula 
milk exclusively. However, increased mortality rates due to non-compliance with these 
guidelines led to drastic policy changes.14 Consequently the World Health Organisation 
(WHO) feeding guidelines in the HIV context for developing countries, in other words 
providing mothers with one message on infant and young child feeding (IYCF), in this case 
exclusive breastfeeding and antiretroviral therapy (ART) for mothers and infants, were 
accepted.15  
ART is an effective way of reducing the viral load, increasing the maternal CD4 count
16 and 
minimising the postnatal HIV mother-to-child-transmission (MTCT) risk through 
breastmilk.17 In 2006, the WHO released a prevention of mother-to-child- transmission 
(PMTCT) of HIV consensus statement that elicited guidelines on the provision of ART to 
mother and infant pairs as well as the appropriate feeding guidelines.18,19 South Africa 
accepted these guidelines in August 2011 and they were implemented in April 2012. The 
guidelines include the provision of ART to pregnant and lactating mothers who needed anti-
retroviral management, and provided their infants with prophylaxic ART treatment. In 
addition, exclusive breastfeeding is recommended from birth until six months and 
thereafter breastfeeding should be accompanied by the introduction of appropriate 
complementary foods.19-21 Continued breastfeeding until 12 months of age is 
recommended.21 This ART and IYCF strategy has been shown to be highly effective in 
preventing MTCT of HIV.18 
 
The following sections provide a brief description of the current ART product description, 
ART regimes and the associated complications with the use of treatment.  
1.3 ANTIRETROVIRAL THERAPY PRODUCT DESCRIPTION 
Drug selection is a multifaceted process with six major anti-retroviral (ARV) drug classes and 
25 drugs: 
 Nucleoside/nucleotide backbones: These are considered the pillar of ART and are 
provided in pairs: 





RNA  DNA 
Host 
cell 
o Nucleoside analogues/ nucleoside reverse transcriptase inhibitors (NRTI): 
These interfere with DNA synthesis of HIV by incorporating defective building 
blocks into HIV DNA, preventing chain completion. The site of action is 
indicated by a green arrow in Figure 1.1. Drugs include: tenofovir and 
emtricitabine; abacavir and lamivudine or lamivudine and zidovudine.21,22 
o Non-nucleoside reverse transcriptase inhibitors (NNRTI): These interfere 
with reverse transcriptase enzyme’s ability to convert the HIV RNA to HIV 
DNA. The site of action is indicated by a yellow arrow in Figure 1.1. Drugs 
include: efavirenz and nevirapine. 21, 22 
 Protease inhibitors (PI): These oppose the protease enzyme that HIV uses to 
produce infectious viral components. The site of action is indicated by a blue arrow 











Figure 1.1: Major antiretroviral classes. Source: Adapted from University of Washington’s 
classification of ART classes. Available from: 
http://www.chartcaribbean.org/careofplwa/pdfdcouments/subpdf/Section%20IV%20new/I
V-2 (classes%20and%20characteristics).pdf.22 
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1.4 CURRENT SOUTH AFRICAN ARV REGIMENS  
In 2013, fixed dose combination (FDC) therapy, a one-pill combination of tenovovir, 
emtricitabine and efavirenz, was introduced as first-line treatment. In 2014, the eligibility 
criteria for pregnant women for the initiation of ART were increased from a CD4 count of 
≤350 to a CD4 count of 500 cells/mm
3 and the PMTCT programme adopted a B+ method that 
entitled all pregnant and lactating women to lifelong  ART regardless of HIV status or stage 
of disease. Pregnant and lactating women who initially test HIV negative should have the 
test repeated after and then every three months throughout the duration of pregnancy and 
lactation as 4% of all women test positive three months after the initial test.24  
1.4.1 Adverse Metabolic Effects of Human Immunodeficiency Virus Treatment Schedules 
The introduction of highly active antiretroviral therapy (HAART) in the 1990s was a huge 
advancement in the treatment of HIV by suppressing HIV RNA replication and significantly 
reducing HIV-related morbidity and mortality.24 
There is biochemical and clinical proof that HAART may induce changes in biochemical and 
metabolic profiles such as glucose and lipid profiles, bone metabolism and endocrine 
abnormalities.25,26  These potential changes are depicted in Table 1.1. 
  
Stellenbosch University  https://scholar.sun.ac.za
6 
 
Table 1.1: Highly active antiretroviral therapy (HAART)-related metabolic abnormalities 
HAART-related effects 
Lipodystrophy  Lipoatrophy 
 Lipohypertrophy (fat accumulation) 
Dyslipidaemia  ↑ Triglycerides 
 ↓ High density lipoprotein (HDL) cholesterol 
 ↑ Total and low density lipoprotein (LDL) 
cholesterol 
 ↑ Hepatic de novo lipogenesis 
 ↑ Small, dense LDL particles 
Glucose tolerance and 
insulin resistance 
 ↓ Glucose tolerance 
 ↑ Fasting insulin and proinsulin 
 ↑ Proinsulin: insulin ratio 
 Increased C-peptide 
Endocrine   Bone and mineral: osteopenia and osteoporosis 
 Thyroid: hypothyroidism 
 Adrenal: mineralcorticoid, glucocorticoid or adrenal 
androgen dysfunction 
 Pituitary: hypercorticosolaemia or glucocorticoid 
resistance 
 Glucose intolerance 
Source: Adapted from Anuurad et al.25 
1.4.2 Highly Active Antiretroviral Therapy (HAART)-Associated Lipodystrophy 
With the introduction of ART, the clinical picture of the HIV-infected person changed from 
emaciation to body shape abnormalities and morphological features associated with glucose 
intolerance and lipid disturbances, such as central obesity and peripheral fat loss.27-29 The 
syndrome, ‘HIV lipodystrophy’, was coined. However, it soon became evident that it is not a 
single syndrome, because some patients present with lipoatrophy only, others with central 
fat accumulation and others with both.30 The prevalence of HIV lipodystrophy ranges from 
10 to 80% according to different definitions used. One should view lipoatrophy and fat 
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accumulation as two separate syndromes as both are associated with different mechanisms, 
risk factors and ART schedules.29 
Lipoatrophy is the loss of subcutaneous fat in the face (buccal and temporal region), 
extremities, abdomen and buttocks. In contrasting to HIV-wasting syndrome, HIV-associated 
lipoatrophy is associated with subcutaneous fat loss with preservation of the lean muscle 
tissue.30 Evidence shows that NRTIs, specifically the thymidine analogues- stavudine and 
zidovudine, are responsible for metabolic changes related to lipoatrophy. Studies also 
indicated that efavirenz minimally contributes to lipoatrophy.32 These changes are a result 
of NRTI-induced inhibition of mitochondrial DNA polymerase gamma and mitochondrial 
toxicity.33 PI’s have not been shown to induce lipoatrophy.34 
Fat accumulation (lipohypertrophy) is the result of a metabolic abnormality that causes 
surplus fat accumulation in the trunk, dorsal area and abdomen (central obesity). There may 
also be fat deposition in the liver, muscles, myocardium and epicardium. It is suggested that 
a defect in peripheral adipocytes causes an increase in the circulation of free fatty acids. The 
latter are then deposited in the visceral adipose tissue due to higher lipid turnover and –
uptake.26 ART-related hypertrophy has not been linked to a specific ART agent or class, but 
relates more to the host’s risk factors.29 Initially it was believed that PI ARV drugs caused fat 
accumulation; however, patients who had never received PI antiretroviral drugs also 
showed signs of fat accumulation.25 In addition, numerous longitudinal studies failed to 
show an association between PI’s and lipohypertrophy.26, 30 Risk factors for fat deposition 
include: advanced age, female sex, elevated baseline triglycerides and elevated body fat 
percentage.35 There is also evidence to show that the fat accumulation in HIV-infected 
patients on ART may reflect the global obesity epidemic rather than the effects of HIV 
infection or ART use alone.31 However, the Multicentre AIDS Cohort Study illustrated that 
HIV-infected men had a faster increase in waist circumference and advanced size of dorsal 
fat pad (buffalo hump) than HIV-uninfected men.36 Some studies have also shown that the 
quality of the diet of HIV-infected individuals is poor and relates to increased visceral fat 
deposition.37  
Furthermore, HAART-associated lipodystrophy causes a reduced expression of LDL that 
results in increased serum levels of LDL.26 A decrease in HDL and triglycerides is also 
observed. These metabolic abnormalities are similar to those of patients with metabolic 
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syndrome. Changes are evident in advanced HIV disease as well as in asymptomatic HIV-
infected patients.25 
Mitochondrial changes are also evident in HAART-associated lipodystrophy. Inhibition of 
mitochondrial DNA-polymerase y causes mitochondrial DNA exhaustion in respiratory chain 
dysfunction that ultimately leads to reduced energy production in cells. The latter promotes 
metabolic disorders in adipocytes, lipodystrophy and increased plasma lipid levels. Both, 
NRTI’s and PI’s regimens, have been shown to induce changes in mitochondrial DNA-
polymerase y.26 
1.4.3 Glucose Abnormalities and Insulin Resistance 
Insulin resistance, glucose intolerance and Type II Diabetes Mellitus are included in the 
plurimetabolic syndrome associated with HAART. The mechanism by which glucose 
metabolism is adversely affected is poorly understood; however, it is suggested that PI’s 
have an inhibitory effect on glucose transport. Furthermore, there is evidence to show that 
PI’s harmfully affects beta-cell function.38 Hyperglycaemia is consequential due to multiple 
factors: decreased glucose tolerance, increased peripheral insulin resistance, lower insulin 
clearance rate and increased fasting insulin.  Increased cortisol levels also contribute to 
defective glucose metabolism.25  
A recent observational study in Costa Rica found the prevalence of insulin resistance in HIV-
infected patients receiving HAART to be 34.2%. Interestingly, this figure is double the 
prevalence of insulin resistance in the general population in Costa Rica. Eighty eight percent 
of the HIV-infected patients were on an NRTI-based regimen.39  
1.4.4 Bone and other Endocrine Abnormalities 
The prevalence of bone demineralisation is high in HIV-infected women.  The contribution 
of HIV-infection and treatment regimens is uncertain. In an observational study, HAART was 
associated with osteopenia and osteoporosis. The reslts were more significant when PI’s 
were used.40 PI’s are powerful inhibitors of the cytochrome P450. Three cytochrome P450 
oxygenases are involved in controlling the serum 1,25 dihydroxyvitamin D3 (1,25(OH)2D3), 
responsible for vitamin D3 activities in bone tissue. An in vitro study illustrated that PI’s 
suppress the bioactivation of 25- and 1α-hydroxylase, which are vital in 1,25(OH)2D3 
synthesis.41  
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The severity of disease influences metabolic parameters. In an Iranian observational study a 
lower CD4 count (<250) was associated with low triglyceride and parathyroid hormone 
levels. Patients on an NRTI-regimen alone had lower levels of calcium but a regimen with an 
NRTI in combination with a PI or NNRTI was associated with an increased phosphorus 
level.27  
In view of the metabolic abnormalities associated with ART, the question arises what the 
effects on breastmilk composition could possibly be. A recent South African observational 
study showed no differences in the nutritive breastmilk composition (total energy, protein, 
carbohydrates, fat, calcium and phosphate) of HIV-infected women on ART compared to 
ART-naïve women.9 However, the effects of HIV and ART on the breastmilk composition of 
mothers giving birth to premature infants are largely unknown. 
The following section describes the effects of HIV and ART on birth outcomes. 
1.5 MATERNAL HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND BIRTH 
OUTCOMES 
The heavy burden of maternal HIV infection has contributed to the prevalence of adverse 
pregnancy outcomes.42  In developing countries, such as South Africa, maternal HIV infection 
may be associated with premature birth;5, 6 however, data from the developed world 
indicated no association between maternal HIV infection and premature birth.2 Infants born 
to HIV-infected mothers were found to have direct adverse effects on organ systems such as 
the central nervous system, thymus and immune system that may affect growth,6 
neurodevelopment, metabolic and other childhood aberrations.43, 44 These adverse effects 
correlate directly with the stage of HIV infection.5 
Furthermore, the effects of HAART on birth outcomes are still indefinite. In HIV-infected 
mothers the role of HAART in the enhancement of maternal health and PMTCT of HIV is 
widely supported by the literature.45-47  When HAART is available, HIV transmission can be 
reduced substantially to 1- 2% in better-resourced settings,48 ; however, it is largely 
uncertain what the effects of in utero exposure to HAART are on premature birth.49  
Combination ARV regimens (≥3 ARV drugs), are recommended for all pregnant women with 
CD4 count ≥350cells/mm
3 but the risk combination therapy for preterm birth is unclear.50 A 
meta-analysis of 14 studies found no increased risk of premature births for women on ART 
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compared to women on no ART, but there was an increased risk for women on PI compared 
to non-PI regimens to deliver babies prematurely.50, 51 Later studies showed conflicting 
results concerning combination ART regimens, and specifically PI’s, and premature birth.50 A 
randomised control trial in Botswana  showed a two-fold increase in the preterm birth rate 
for women who received lopinavir/ritonavir compared to those who received a triple 
nucleoside ART regimen.52 In contrast, in 2011 a retrospective cohort study that reviewed 
data from 3273 HIV-infected women from Malawi and Mozambique receiving triple ART 
showed that the use of ART reduced adverse pregnancy outcomes. The incidences of 
stillbirths/abortions and prematurity were significantly increased in women who did not 
receive ART compared to women on ART. The results also showed that LBW was not 
associated with ART use.7 
African studies reported conflicting results with respect to maternal HIV-infection and LBW 
deliveries.53-62 Intra-uterine growth restriction (IUGR), defined as a foetal weight, length or 
head circumference of <10th centile; may, among other factors, be responsible for 
premature delivery.1 Premature birth and IUGR are major causes of paediatric morbidity 
and mortality.1  
IUGR can be symmetrical (weight, length and head circumference is small for gestational 
age [SGA]), indicating an abnormal process present since early in the pregnancy, or 
asymmetrical (sparing of the head circumference and length), indicating a pathology later in 
the pregnancy.63 In an SA study among IUGR premature infants, there was a nonsignificant 
increased trend for HIV-infected mothers to give birth to a symmetrically growth-restricted 
infant (29%) compared to an asymmetrically growth-restricted infant (23%).64 This possibly 
indicates the perinatal effects of maternal HIV status.64 Studies conducted in the developed 
world showed no association between in utero exposure to HAART and IUGR,5,65,66 but 
results obtained from the developing world are conflicting.66-68 
1.6 MATERNAL NUTRITIONAL STATUS AND BIRTH OUTCOMES 
Maternal nutritional status during pregnancy is a key factor in determining foetal growth 
and anthropometrical parameters at birth. In South Africa poor household food security and 
the effects of HIV/AIDS Wasting Syndrome (or the combination therof) may contribute to 
maternal undernutrition.69 In the undernourished mother, the supply of maternal- foetal 
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nutrients are deminished thereby retarding foetal growth. Evidence suggests that chronic 
maternal undernutrition adversely affects foetal growth more than poor nutrition during 
pregnancy alone.70 In an SA study, birth weight was inversely associated with maternal HIV 
status and mid-upper arm circumference (MUAC).4 Moreover, in multiparous pregnancies, 
foetuses compete for available nutrients ultimately resulting in IUGR.71 
Foetal growth is susceptible to maternal nutritional deficiencies (specifically of protein and 
micronutrients) during the pre-implantation period as well as the period of rapid placental 
growth.71 Compromised synthesis of nitric oxide, an important vasodilator and angio-
genesis factor, and polyamines (involved in protein synthesis) produces proof that maternal 
over- and undernutrition can both be responsible for IUGR.71 Furthermore, maternal 
nutritional status can be responsible for modifications in gene expression of the foetal 
genome through DNA methylation and histone adjustments.71 Changes in the intrauterine 
nutrition - and endocrine environment may have serious and permanent consequences for 
the infant through foetal programming. This hypothesis proposes that chronic diseases; 
vascular, endocrine or metabolic, that present later in life, may be a result of early foetal 
adaptations to malnourishment.72,73  
In addition to undernutrition, the incidence of overweight and obesity, especially in women, 
is rising dramatically in South Africa.69 Overnutrition is associated with various health 
problems. Maternal overnutrition impedes placental growth and ultimately leads to growth 
faltering, significantly increasing neonatal morbidity and mortality.72 
In view of the vulnerability of the premature infant, breastmilk is regarded as an important 
feeding strategy for the premature infant.8 In the following section breastmilk and its 
nutritive components will be discussed to illustrate the importance of optimally feeding the 
HIV-exposed premature infant. 
1.7 BREASTMILK AS A THERAPEUTIC STRATEGY FOR PREMATURE INFANTS 
It is well documented that irrespective of HIV infection, ART regimen and maternal 
nutritional status, LBW premature infants are more vulnerable to complications and death 
than their term counterparts.4, 74 Premature infants have higher nutritional requirements 
during the neonatal period to facilitate growth compared to any other stage of life. This is 
due to several mechanisms including: i) LBW or IUGR resulting from a decreased time 
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exposed to intrauterine nutrition ii) medical complications related to prematurity, including 
hypoxia, hypotension, acidosis that ultimately increase nutritional requirements and iii) 
immature organ systems such as an immature gut, decreased enzymatic activity, reduced 
gastric motility and corticosteroid therapy. Therefore, it is vital to provide optimal 
nutritional therapeutic strategies to ensure better outcomes. Nutritional support corrects 
growth restriction and facilitates an appropriate weight gain tempo, which is nearly double 
that for a term neonate.75 Feeding a premature infant breastmilk is the gold standard for 
feeding and has been proven to reduce morbidity and mortality. Human breastmilk is ideal 
for the neonate’s immature organs that are not well adapted to responding to excesses or 
deficiencies of certain nutrients.76  
 
It is well documented that early nutrition has important effects on the short- and long-term 
outcomes in premature infants. The short- and long-term benefits of feeding a premature 
infant breastmilk are depicted in Table 1.2. 
  
Table 1.2: Short- and long-term benefits of providing breastmilk to premature infants  
Short-term benefits Long-term benefits 
 Improved gastro-intestinal 
maturation 
 Improved nutrient absorption 
 Advanced cognitive development 
 Improved eye development 
 Improved host defence against 
infections 
 Stronger mother-infant bonding 
 Improved protection against 
Necrotizing Enterocolitis (NEC) 
 Advanced mental development 
 Improved motor development 
 Higher intelligence scores 
 Better visual function 
 Healthier body composition in 
adolescence 
 Lower incidence of metabolic 
syndrome in adult years 
Adapted from: Picciano MF, et al. 76  
1.8 THE NUTRITIONAL COMPOSITION OF PRETERM BREASTMILK 
Table 1.3 depicts the nutritional composition of preterm breastmilk according to the 
number of days postpartum. 
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Table 1.3:  Changes in preterm breastmilk composition in the neonatal period 
Component  Preterm breastmilk per 100ml 
Day 3  Day 7 Day 14 ≥ Day 21 
Energy (kCal) 49 67 70 67- 78 
Carbohydrate (g) 6.2 6.9 7.0 7.3 
   Lactose (g)    6.7-7.3 
Total nitrogen (g) 0.4 0.32 0.27 2.89 
Total protein (g) 2.0 1.6 1.3 1.62-2.2 
   Casein (g) 0.6 0.48 0.4 0.49 
   Whey (g) 1.4 1.12 0.91 0.5 
Total lipids (g/dl) 1.6 3.5 3.9 3.5-4.8 
Water-soluble vitamins 
   Ascorbic acid (mg)    4.4 
   Thiamine (µg)    8.9 
   Riboflavin (µg)    27 
   Niacin (mg)    210 
    Pyridoxine (mg)    6.2 
   Folate (µg)    3.1 
   Vitamin B12 (µg)    0.02 
   Pantothenic acid (µg)    230 
   Biotin (µg)    0.54 
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   Vitamin A (IU)    48 
   Vitamin K (µg)    2 
   Vitamin D (IU)   8  
   Vitamin E (IU)    0.39 
   Major minerals 
      Calcium (mg)    20-29.2 
      Magnesium (mg)    2.43-4.14 
      Phosphorus (mg)    9.3-15.5 
      Sodium (mg)    24-51 
      Potassium (mg)    42-70 
      Chloride (mg)    58 
   Trace minerals 
      Iron (mg)  0.135  0.09 
      Zinc (mg)  0.37-0.62 0.98 0.37 
      Copper (mg)  0.506-0.57 0.489 0.038 
     Manganese (µg)  0.133 0.127 0.125-0.36 
     Selenium (µg)  11.8 11.4 2.4-11.4 
Adapted from: Koletzko B,78 Anderson DM et al,79 Bishara R et al,80 Bauer J, Gerss J,81 Kim SJ et al,82 Ronayne de Ferrer PA, etal,83 Tsang RC et 
al.84 
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1.8.1 Protein and amino acid composition of preterm breastmilk 
The proteins in human breastmilk are hormone regulated and therefore the composition 
varies.85 Breastmilk has two protein fractions defined by the solubility in acid: whey and 
casein. Preterm breastmilk has a whey protein predominant (whey:casein = 70:30) 
composition to facilitate rapid gastric emptying, enhance protein digestion and contains 
other whey-containing proteins resistant to hydrolysis (lysozyme, lactoferrin and 
immunoglobulin A involved in the enhancement of the host defence system).86 Whey 
predominance also facilitates an optimal amino acid composition associated with enhanced 
brain function. Premature infants fed either mother’s own milk; or a whey - or casein 
dominant formula were compared in a randomised controlled trial. Levels of methionine, 
phenylalanine and tyrosine were the lowest in the group that received breast milk. High 
levels of these amino acids impede brain development.87 Of the 70% whey, alpha-
lactalbumin, a component of the lactase synthetase complex, makes up 41% of the whey 
and 28% of the total protein content. The high proportion of alpha-lactalbumin is unique to 
human milk.88 Alpha-lactalbumin is involved in mineral absorption (especially calcium and 
zinc), shows antibacterial and immune stimulatory actions and has an anti-infective property 
by enhancing apoptosis.89 
 
Conditional essential amino acids (particularly cysteine and taurine) can be synthesised by 
de novo synthesis in adults, but not by premature infants due to biochemical immaturity.  
Preterm breastmilk is rich in cysteine which is involved in some important metabolic 
functions such as growth and protein synthesis; and serves as the precursor of the potent 
antioxidant, glutathione.90 Preterm breastmilk is also abundant in the amino acid taurine, 
which is imperative for fat absorption, improves the maturation of Auditory Brainstem 
Evoked Response (ABER)a and is present in the osmoregulation of the central nervous 
system.91  
 
                                                          
a
 Brainstem auditory evoked response (BAER) is a test to measure the brain wave activity that occurs in 
response to clicks or certain tones. 
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1.8.2 Carbohydrate composition of preterm breastmilk 
Carbohydrates in preterm milk mainly consist of lactose and oligosaccharides (40% of the 
total energy). Lactose is well absorbed and is responsible for activating intestinal lactase. 
About 10% lactase is excreted in the stool for the functions of serving as a stool softer, the 
absorption of minerals and the beneficial composition of faecal bacteria.86 Human milk 
oligosaccharides (HMOs) are studied frequently in the literature for their prebiotic effects 
and microorganismic anti-adhesive properties, preventing pathogenic attachment to the 
intestinal epithelial cells.92 In a recent SA study, Van Niekerk et al made an interesting 
discovery about HMO oligosaccharides that differed between HIV-infected and HIV-
uninfected mothers who had given birth to premature infants. HIV-infected mothers had a 
higher HMO content in their breastmilk than HIV-uninfected mothers.10  
1.8.3 Lipids and fatty acid composition of human preterm milk 
Breastmilk comprises 98% triacylglycerols, 1% phospholipids and 0.5% cholesterol esters.93 
Lipids are emulsified in the aqueous phase of milk. Lipid globules are covered by bipolar 
materials that act as an emulsion stabilizer.94 Half of the calories in preterm breastmilk are 
derived from lipids. Lipids act as an important energy source for the growing infant81 and 
the long-chain fatty acids in breastmilk has been shown to enhance brain and visual 
development in preterm infants.95   
Because of the immaturity of the preterm infant’s digestive system, lipids in preterm 
breastmilk are adapted for optimal digestion. Due to the complex structure of the lipids and 
the presence of fatty acids and bile salt-stimulated lipase, the lipid composition in preterm 
breastmilk is of high suitability as these characteristics promote absorption. Medium-chain 
triglycerides account for less than 12% of the total fat in preterm milk, which also facilitates 
enhanced absorption.96,97  
1.8.4 Fatty acids in preterm breastmilk 
Essential fatty acids are structural constituents of all tissues and are crucial for cell 
membrane synthesis of the brain, retina and neural tissue.  Fatty acids also serve as 
precursors for eicosanoids that regulate many cell and organ functions.95  
The maternal diet largely determines the ratio of fatty acids in breastmilk.98 Humans cannot 
synthesise essential fatty acids and therefor rely on the diet for the provision of essential 
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fatty acids, such as linoleic acid (LA), alpha-linolenic acid (ALA) and other long-chain 
polyunsaturated fatty acids (LC-PUFA) metabolites. During the last trimester of pregnancy 
and during the first year of life, docosahexanoic acid (DHA) is incorporated into the cells of 
the brain and retina.99 The cerebral concentration of arachidonic acid (AA) and DHA 
increases rapidly during the growth spurt that occurs in the final trimester and the first few 
months thereafter.100 Specifically DHA, the precursor of omega-3-polyunsaturated fatty 
acids (PUFAs), has been found to enhance cognitive function and improve visual acuity in 
term and preterm infants.101, 102 Throughout the final trimester of pregnancy the foetus 
requires 40- 60mg/kg omega-3-PUFA per day.102 In a regression analysis among a group of 
73 children 6.5 years of age, a study found that 76% of intelligence quotient (IQ) variance 
could be attributable to the period of breastfeeding, week of gestation and the DHA and AA 
content in breastmilk. 102  
 
An infant is incapable of producing DHA and is dependent on breastmilk to provide these 
fatty acids.101 Lucas and colleagues showed that premature infants fed mother’s own milk 
(human breastmilk) had higher developmental scores at 18 months. The researchers later 
showed that these infants performed better in intellectual tests at 7.5 and 8 years of age. 
The advantage in IQ-score was breastfeeding dose dependent.103 Additionally, the provision 
of breastmilk revealed advantages for visual development and psychomotor development at 
18 months.103 Retinopathy, a complication of prematurity, was less prevalent among 
premature infants fed breastmilk. Furthermore, breasmilk might relieve the degree of 
retinopathy. The improvement in visual function is related to the LC-PUFA and antioxidant 
content of breastmilk that improves the integrity and function of the retinal 
membranes.95,104  
  
Some studies have reported positive outcomes in visual function, long-term 
neurodevelopment and growth when omega-3 LC-PUFAs were supplemented in pregnancy 
and/or lactation. In a review by Campoy and colleagues, they warned to interpret the results 
with caution because the studies included might have methodological flaws.105  
 
LC-PUFAs are important for their part in modulating the immune system. In breastfed 
infants, LC-PUFAs, specifically DHA and AA, play an important role in T-cell development and 
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function.106    Furthermore, there is evidence that LC-PUFAs exhibit virucidal capacity against 
encapsulated viruses.107, 108 A Tanzanian case-control study nested in a cohort study showed 
that increased concentrations of omega-6 PUFAs protected against MTCT of HIV.107 Hsu 
proposed that HIV-infection destabilised the K+-channel, causing destruction. When DHA 
and AA are supplemented, the ability of the cell membrane to maintain its stability is 
restored.109  
 
1.8.5 Cholesterol composition of preterm breastmilk 
Cholesterol, an integral part of human cell membranes, is found in abundance in breastmilk. 
The cholesterol quantity in breastmilk can fluctuate during the course of the day.110 Studies 
have shown that breastfed infants have lower blood cholesterol levels in adulthood.111, 112 It 
is hypothesised that exposure to high levels of cholesterol during lactation has a metabolic 
advantage on fatty acid synthesis that protects agains hypercholesterolaemia later in life.113  
1.8.6 Vitamin composition of preterm breastmilk 
Premature infants’ vitamin requirements are higher than term infants’ due to higher 
utilisation and losses. There are currently insufficient data to know the exact amounts 
needed. Breastmilk provides insufficient quantities of vitamins to meet the high demands of 
preterm infants.114 Table 1.4 provides a summary of the vitamin composition of premature 
breastmilk.  
 
Data on the breastmilk vitamin composition of HIV-infected women who gave birth to 
premature infants are scarce. However, it is known that HIV-infected patients frequently 
have vitamin deficiencies.115 It is recommended that lactating women take a multivitamin 
during the period of lactation. In the absence of ART, interventions that enhance immunity, 
such as vitamin supplementation during lactation, may decrease the risk of MTCT of HIV 
through breastmilk.116  
 




   
Table 1.4: Summary of vitamin composition in breastmilk of women who gave birth to premature infants 
Vitamin  Description  
Vitamin A  The vitamin A content of premature breastmilk is dependent on dietary intake.78, 85 The average vitamin A 
content of breastmilk is 75 mcg/dL (280IU/dL) and some of it is present in the form of β-carotene.  
 In a Kenyan randomised control trial, severe vitamin A deficiency (<20 mcg/dL) was associated with HIV-
infection, thus increasing the risk of MTCT.117 
 However, vitamin A supplementation was associated with an increased risk of MTCT of HIV through 
breastmilk.116 
Vitamin D  Vitamin D is present in the aqueous and lipid fractions of human breastmilk. The form in which vitamin D is 
available is 25-OH2 vitamin D. Infants require sunlight exposure to convert 25-OH2 vitamin D to the – active 
form 1,25-(OH)2 vitamin D. A ten-fold increase in the vitamin D content of breastmilk is possible when the 
mother obtains exposure to sunlight.85, 118  
 Vitamin D deficiency is prevalent (55.6%) in HIV-infected patients119 and is associated with accelerated 
disease progression.120 
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Vitamin E  Colostrum has a high concentration of vitamin E (600 mg/l), which decreases by a third in mature preterm 
breastmilk.78 
 The average vitamin E (tocopherol) content of breastmilk is 40 mcg/g of lipid.85,121 The vitamin E content is 
adequate to fulfil the neonate’s requirements and is present in the beta- and gamma-tocopherol in mature 
milk.85 The amount of vitamin E increases during the course of a breastfeed, and hindmilk has four times the 
amount of vitamin E than foremilk.78 
Vitamin K  Vitamin K is scarce in breastmilk (2.3mcg/dL) and infants require a postnatal vitamin K injection (0.5-1.0 mg) 
to avoid a deficiency.85 
Vitamin B  Unlike the other water-soluble vitamins, vitamin B12 and folic acid are whey protein-bound and are not 
influenced by the maternal diet.  Known factors to influence the composition are gestational age and 
hormones.85 
  In a randomised control trial lower baseline vitamin B12 levels correlated with lower CD4 count.
115 
Vitamin C  Dietary intake and not supplemental intake strongly affects the vitamin C concentration in breastmilk.122 
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1.8.7 Mineral composition of breastmilk 
Minerals in breastmilk are central in the optimal infantile growth. Breastmilk has a lower 
mineral content compared to other mammalian milk to reduce the strain on the kidneys and 
because humans show a slower growth velocity to other mammals. The osmolarity of 
breastmilk is largely dependent on the mineral content.85 Key minerals in breastmilk include 
sodium (Na), phosphorus (P), calcium (Ca), magnesium (Mg), and chloride (Cl).123  Most of 
the minerals decrease over a few months of breastfeeding, with the exception of 
magnesium that increases.123 Studies showed that the net magnesium retention from 
preterm breastmilk is equal to the intrauterine requirements.125, 126 The bioavailability of 
minerals, such as calcium, magnesium, iron and zinc, is excellent and this not only improves 
the absorption of these minerals, but also reduces the burden on the lactating mother to 
produce large quantities of these elements.85, 127  
 
The minerals selected for discussion in this section have relevance to section 2.11.2.3 in the 
methodology. These minerals relate to the growth and development of premature infants.  
i. Phosphorus (P) 
One of the major roles of phosphorus for premature infants is for ensuring dental-128 
respiratory-129 and bone health.130 
One study found that among 76 very-low-birth-weight (VLBW) infants, 62% had enamel 
defects associated with hypophosphataemia. The results indicated that the only significant 
variable in the logistic regression analysis was that infants with a 1-mg/dL increase in 
serum phosphorus levels had a 68% reduction in the odds of having enamel hypoplasia.128 
Premature infants are at substantial risk to develop respiratory distress syndrome and 
chronic lung disease. Phosphorus, among other nutrients, was identified to be significant in 
lung development and function.129 
Premature infants are at a high risk of developing osteopenia of prematurity due to multiple 
reasons: i) Reduced stores due to a shorter gestation, ii) Inadequate supply of phosphorus 
(and other nutrients) due to problems in establishing full enteral feeding/ breastfeeding, iii) 
low concentration of phosphorus in breastmilk  iv) vitamin D deficiency and v) missing a 
period of mineral accretion in the last trimester of pregnancy.130 In order to achieve bone 
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mineralization, premature infants require an enteral supply of 60- 90mg/kg/day of 
phosphorus salts.131 Given the low concentration of phosphorus in breastmilk, it is 
impossible to achieve the requirements without fortification. It is considered standard 
practice to fortify breastmilk of mothers of premature infants.132 The breastmilk fortifier 
available in South Africa (FM85) provides 900mg P/100g which is sufficient to meet 
phosphorus needs of premature infants  on full feeds.133 
ii. Iron (Fe) 
Although the iron concentration in breastmilk is low compared to other mammals, it is 
highly bioavailable. This can be illustrated by the fact that only 10% of iron in cow’s milk is 
available for absorption, compared to almost half (49%) of breastmilk that is bioavailable. 85, 
134  
Premature infants experience a sudden reduction of erythropoiesis at birth, which leads to 
anaemia of prematurity. Additionally, premature infants are born with low iron stores and 
often lose blood during phlebotomy.135 It is recommended that preterm infants receiving 
breastmilk be supplemented with 2- 4mg/kg/day iron starting on day 14 of life.136 A 
systematic review showed that preterm infants who received iron supplementation, had 
higher haemoglobin levels and -iron stores and were less likely to have iron deficiency 
anaemia.137 
iii. Zinc (Zn) 
Many studies assessed the zinc concentration of breastmilk, largely because of its role in 
growth, 83, 136 cell differentiation and macronutrient metabolism.139 Growth is therefore the 
major factor in determining zinc requirements.139 A preterm infant needs to retain 25% of 
the zinc to master in utero accumulation.140 The zinc bioavailability in preterm breastmilk is 
higher than other in mammalian milk due to the strong binding of zinc to casein. This is 
demonstrated by the fact that 60% of zinc in preterm breastmilk is absorbed compared to 
14% in preterm formula.139 The zinc concentration in human breastmilk is not dependent on 
maternal diet. The breastmilk zinc concentration in preterm milk is significantly higher than 
term breastmilk and zinc concentration is highest in transitional milk and then decrease over 
a period of breastfeeding.139 
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The results of a Cochrane review by Siegfried and colleagues indicated that there are 
currently no indications to supplement HIV-infected pregnant or breastfeeding women with 
zinc. They suggested that specific requirements for HIV-infected breastfeeding women 
should be developed and that more research should be done on micronutrient 
supplementation during the different stages of HIV.141 
iv. Copper (Cu): 
The copper content in preterm breastmilk is adequate to fulfil the premature infant’s 
requirements. Copper is vital in anti-oxidant defences and forms part of superoxide 
dismutase that protects cell membranes against reactive oxygen species. Copper is stored in 
the liver and transported to peripheral tissues bound to ceruloplasmin whose production 
starts six to 12 weeks postnatally. However, copper deficiency is rare in neonates. Copper 
deficiency presents as a hypochromic anaemia not responsive to ironsupplementation.139 
v. Other minerals: Selenium (Se) 
Selenium is a potent anti-oxidant and plays an important role in cell-mediated immunity and 
in brain, thyroid and cardiovascular health. HIV-infected people are more likely to have an 
seleniumdeficiency, because the body uses selenoproteins to suppress viral replication or 
the virus uses selenium to generate its own selenoproteins. In a Malawian randomised 
control trial, a sodium selemite dietary supplement did not significantly affect HIV-infected 
breastfeeding women’s breastmilk selenium content. However, the selenium in the dietary 
supplement is not as well absorbed as in many selenium-containing food sources.142 In 
another African trial, selenium supplementation increased HIV-RNA in breastmilk among 
primiparous HIV-naïve women.143 
Preterm breastmilk composition is highly variably. Numerous factors affect preterm 
breastmilk composition between individuals. These include: differences in foremilk and 
hindmilk, stage of lactation, prematurity, maternal dietary intake, maternal nutritional 
status, breastmilk expression technique and pasteurisation methods used. The following 
section will discuss each factor in detail. 
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1.9 FACTORS THAT INFLUENCE THE NUTRITIVE COMPOSITION OF HUMAN BREASTMILK 
1.9.1 Foremilk and hindmilk 
It is well known that the composition of the within-feed nutrient content of breastmilk 
changes to accommodate the infant’s needs.  The water content between the the foremilk 
and hindmilk does not change significantly. Because the lipid content increases linearly with 
the duration of the feed, the energy content of the hindmilk is higher than those of the 
foremilk.71 Lipid amounts in hindmilk are double that in foremilk. Protein and lactose 
decrease during the course of the feed, but this is inversely proportionate to the rise in lipid 
content.144,145 
 
For relevance of data collection procedures, breastmilk samples from the left and right 
breast do not differ significantly with regards to major nutrients (sodium, potassium, urea, 
creatinine, phosphate, calcium, magnesium, protein, carbohydrate and lipids) that 
contribute to more than 90% of the osmotic activity of human breastmilk. The fat content of 
the hindmilk can increase two- to three-fold,144  and phospholipids and cholesterol decrease 
between the foremilk and hindmilk.144 Although the total fat content increases, the fatty 
acid content of foremilk and hindmilk does not differ significantly.146  These findings have an 
impact on the sampling of breastmilk. If the water content of the milk is of interest, the 
sample can be taken at any stage of the feed. However, if the lipid content is of interest, the 
mid-feed sample will give a representative sample. Between-breast variation does 
sometimes occur and thus it is recommended to obtain a sample from each breast. If the 
sodium and potassium content is above the normal values, the possibility of mastitis should 
be investigated.144  
 
Interestingly, in a Nigerian study, VLBW preterm infants were randomised to receiving 
either hindmilk or composite breastmilk for two weeks. The results indicated that the first 
group had significantly better weight gain rates.147  
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1.9.2 Stage of lactation 
The nutritional composition of preterm breastmilk changes according to postpartum 
phase:148 
i. Colostrum is the first secretion of the mammary glands at the time of parturition 
with the goal of providing passive immunity. Breastmilk produced in the first week 
after giving birth is high in colostrum.. 
ii. Transitional milk occurs after colostrum and lasts for one to two weeks. 
iii. Mature milk isthe final milk produced and is comprised of a high percentage of 
water.  
Table 1.5 depicts the nutritive composition between colostrum, transitional and mature 
preterm breastmilk. 
 












60 (45- 75) 2.2 (.03- 4.1) 2.6 (0.5- 2.7) 26 (9- 43) 11 (1- 22) 
Week 2  
(Early Transitional 
Milk) 
71 (49- 94) 1.5 (0.8- 2.3) 3.5 (1.2- 5.7) 25 (11- 39) 15 (8- 21) 
Week 3-4  
(Late Transitional 
Milk) 
77 (61- 92) 1.4 (0.6- 2.2) 3.5 (1.6- 5.5) 25 (13- 36) 14 (8- 20) 
Week 10-12 
(Mature Milk) 
66 (39- 94) 1.0 (0.6- 1.4) 3.7 (0.8- 6.5) 29 (19- 38) 12 (8- 15) 
Adapted from: Gidrewicz, Fenton. 148 
 
As demonstrated in Table 1.5 the total energy, lipids and minerals increase within the first 
month of lactation while the protein content decreases. Similarly, lactose concentration in 
preterm breastmilk has been shown to increase in the first month of lactation.149  




A study that evaluated the changes in fatty acids in preterm breastmilk over 26 weeks of 
lactation showed the following results: The monounsaturated and saturated fatty acids 
remained relatively stable in the six-month period. Linoleic acid and alpha-linolenic acid 
showed an increasing trend from transitional to mature milk (8.7% to 9.9% of the total fatty 
acids). The LC-PUFAs were highest in Week 1 and then showed a decreasing trend.150 
 
1.9.3 Prematurity 
The degree of prematurity affects the composition of preterm breastmilk. The nutrient 
density of preterm breastmilk shows an inverse relationship with gestational age.151 The 
energy content of mature preterm breastmilk varies between 65 and 78kCal/100ml.71 Table 
1.6 depicts the elevated nutrient composition of preterm breastmilk to accommodate 
growth. 
 
Table 1.6: Nitrogen, fatty acid and energy content of preterm and term breastmilk 
Gestational age Nitrogen (mg/dl) Fatty acids (g/dl) Energy (kCal/dl) 
26-31 weeks 297 4.46 78.6 
32-36 weeks 250 3.94 69.0 
Term 259 3.20 66.6 
 
1.9.3.1 Protein composition 
The protein composition of preterm breastmilk is described in Section 1.9.1 of this chapter. 
The protein content of breastmilk is relative to the infant’s age.81 In a systematic review by 
Gidrewicz and Fenton, the true protein content of preterm breastmilk was found to be 
higher by up to 35% (0.7 g/dL) in the first three days after birth compared to term 
breastmilk. After that, the difference decreased by 0.2 g/dL and by weeks 10– 12, the 
difference disappeared.149 Uncertainty exists as to which proteins contribute most to the 
elevated protein content of preterm breastmilk. The degree of difference in composition is 
related to gestational age and level of prematurity.81 
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1.9.3.2 Lipid composition 
Refer to Section 1.8.3 for the complete analysis of lipid composition. The total lipids in 
preterm and term breastmilk did not show a significant difference in the systematic review 
by Gidrewicz and Fenton. However, there was a non-significant elevation in preterm 
breastmilk of 23% in the first three days of lactation.148 
 
In a systematic review of five studies comparing the fatty acid content of term and preterm 
breastmilk, no significant differences were observed for saturated and mono-unsaturated 
fatty acids between term and preterm breastmilk. However, the DHA content of preterm 
breastmilk were significantly higher than in term breastmilk. The mechanism of action is 
related to the maternal LC-PUFA stores. In the case of premature infants, the gestational 
period in which the maternal LC-PUFA were transmitted to the infant was interrupted. This 
resulted in a positive maternal LC-PUFA balance. In addition, a premature infant can only 
consume a limited breastmilk volume and therefore the LC-PUFA concentration of 
premature breastmilk is higher.153  
1.9.3.3 Carbohydrate composition 
The carbohydrate composition of premature breastmilk is discussed in Section 1.8.2. 
Gidrewicz and Fenton found that the lactose concentration was significantly lower in 
preterm breastmilk than in term breastmilk with the exception of a few days where it was 
higher. Although there were limited data on the oligosaccharide content of preterm 
breastmilk, the researchers found it to be similar in preterm and term breastmilk.148  
 
1.9.3.4 Mineral composition 
A complete discussion of mineral composition is given in Section 1.8.7. The mineral and 
electrolyte content of preterm breastmilk is significantly elevated when compared to term 
breastmilk. This is not only to accommodate the increased requirements for growth, but 
also to compensate for the high losses, especially of sodium.79 However, Gidrewicz and 
Fenton found no differences in the calcium and phosphate concentration between preterm 
and term breastmilk.137 In an observational study, Ejezie et al. found preterm breastmilk to 
be significantly higher in iron compared to term breastmilk.154 
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1.9.4 The effect of maternal dietary intake on breastmilk composition 
Various studies assessed the relationship between maternal diet and the breastmilk 
composition under diverse environmental circumstances. A lactating woman can provide 
adequate nutrients even when her diet is deficient in nutrients unless energy deprivation is 
extreme.155 
 
The maternal diet does not characteristically affect the quality or quantity of breastmilk 
protein, even in malnourished women. However, protein supplementation increases milk 
protein concentration, and free amino acid and urea content parallels the quantity and 
quality of maternal dietary protein. A study found that breastmilk nitrogen content was 
higher in women fed a high protein diet (134g protein per day) compared to women fed a 
low protein diet (46g protein per day).156 
Maternal diet affects the lipid profile and more importantly, the essential fatty acid profile 
of breastmilk; however, the total fat content is not affected by the maternal diet.81, 101 
Observational and cohort studies have linked maternal fish intake during pregnancy and 
during lactation to the essential fatty acid content of breastmilk and consequently 
developmental outcomes and IQ. Maternal fish intake did not have a significant effect on 
infant blood mercury levels.157-159 
 
The quantity of water- and fat-soluble vitamins, with the exception of vitamin K, is 
dependent on the maternal diet.81 Deficiencies of water-soluble vitamins are very rare, even 
when the maternal diet and breastmilk contain inadequate amounts.160  Although the 
vitamin B12 content of breastmilk is less determined by dietary intake, low levels have been 
reported in vegan mothers, mothers with pernicious anaemia, undernourished mothers and 
mothers with a poor intake of animal products.161-163 Studies have reported vitamin B6 to be 
the most likely water-soluble vitamin to be deficient in breastmilk. 81, 163 One study found 
that the maternal diet had no effect on the breastmilk concentration of vitamin B6.
164 
Overall, the mineral content of breastmilk does not reflect the maternal serum mineral 
status.124 
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1.9.5 The effect of maternal nutritional status on breastmilk composition 
Pregnancy and lactation are a nutritionally demanding period and can lead to nutritional 
depletion, especially when lactation and a subsequent pregnancy overlap.165,166  The human 
body is uniquely adapted to adjust to the demands of lactation, provided that a well-
balanced diet is consumed.165 The International Dietary Energy Consultancy Group’s 1993 
Annual Report to the Administrative Committee on Coordination/Subcommittee on 
Nutrition concluded that nutritional status did not reflect the lactation capacity of a women, 
except in the case of severe undernutrition (‘famine or near famine conditions’).167  
In theory, the lactating woman has higher nutritional demands to produce adequate 
nutrition for her infant.168 For many women, this is not possible due to social reasons or a 
lack of food security. Women from the developed world have an approximate daily energy 
intake of 2600kCal compared to women of the developing world who consume only 
1600kCal per day.169 Lactating mothers from the developing world often do not meet the 
increased energy requirements during lactation. A diet chronic deficient in energy can lead 
to depletion which ultimately adversely affects breastmilk composition.155 However, 
Prentice et al. illustrated that milk volumes from undernourished women in developing 
countries did not differ from well-nourished women from developed countries.170 In this 
section the many different factors that influence the nutritive composition of human 
breastmilk were discussed. 
 
The following sections (breastmilk expression techniques and pasteurisation) are of 
relevance for data collection procedures described in Section 2.12.4 in the methodology.  
 
1.9.6 Breastmilk expression technique 
Breastmilk expression is done manually or with a breastmilk expression pump.171 In South 
Africa the manual expression method is mainly used as it is cost effective and safe.172 The 
usage of a breast pump is in line with the WHO/UNICEF Code of Marketing of Breastmilk 
Substitutes173 as long as feeding bottles do not accompany the pumps and are not 
inappropriated marketed.  
Stellenbosch University  https://scholar.sun.ac.za
30 
 
The Food and Drug Administration (FDA) recommends FDA approved pumps for the use by 
one mother exclusively, because use by more than one mother increase the risk of HIV-1 
transmission.174 
Manual expression produces a reduced milk volume and is more labour intensive compared 
to breastpump expression. A benefit of manual expression is that there is very little 
equipment to clean and sterilise in comparison with breast pumps.171 Breast pumps are very 
efficient and may pose significant advantages to mothers of preterm infants as they often 
struggle with low breastmilk volumes.175  
Using a pump is a robust way to ascertain the maintenance of breastmilk production for a 
longer period.176 There is little evidence that compares manual and pump expression 
techniques; however, some studies have shown differences in protein, fat, sodium and 
potassium content.177 
 
1.9.7 Pasteurisation of breastmilk 
Van Wyk et al. described the effect of the Pretoria pasteurisation method on the breastmilk 
composition of 32 Xhosa speaking South African mothers with VLBW premature (<34 weeks 
gestation) infants. Each milk sample was halved- one half was kept raw and the other was 
pasteurised. The results indicated no statistical difference in the breastmilk composition 
pre- and post-pasteurisation.178 
Another study compared the effects of Pretoria pasteurisationb and Flash-heat 
pasteurisationc on the nutritional properties in breastmilk. Both methods caused minimal 
nutritive losses on vitamins A, -B6, -B12, -C, -folate, -riboflavin and -thiamine. However, the 
Flash-heat Pasteurisation method was more effective in inactivating HIV.The WHO 
recommends the Flash heat pasteurisation method to prevent MTCT of HIV.179 
Concerns in pasteurising breastmilk were that preterm infants showed a decreased growth 
velocity, because the pasteurisation process destroyed the heat-labile lipase and that the 
                                                          
b
 This method uses the principle of heat transfer from 450 ml water heated to boiling point in an aluminium 
pot to a smaller volume of breastmilk in a glass jar inserted in the water. Milk is heated to a temperature of 52-
62°C for 10-15 minutes. Thereafter, milk is cooled to room temperature/37°C. 
c
 In this method expressed breastmilk in a glass jar is placed in 450 ml water in an aluminium pot over a heat 
source. Water is brought to boiling point/100°C (milk reaches an approxiamate temperature of 72°C) and 
thereafter cooled down to room temperature/37°C. 
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composition of donor breastmilk, used for pasteurisation, differs significantly that of 
preterm milk.176 Pasteurisation not only destroys the harmful pathogens in breastmilk, but 
also diminishes the bacteriostatic effect which can result in pathogenic contamination.180 
 
1.9.8 Effect of HIV-infection status on human breastmilk composition 
The results obtained by Van Wyk et al indicated that the breastmilk of HIV-1 positive 
mothers was as healthful as the breastmilk of HIV-1 negative mothers concerning the 
nutritive composition alone.178  Another SA study found that HIV-infected women’s 
breastmilk had elevated protein levels and decreased calcium levels compared to breastmilk 
of HIV-uninfected women who gave birth to term infants. There was no significant 
difference in breastmilk composition of HIV-infected women receiving ART compared to 
HIV-infected women not receiving ART (HIV-naïve). However, there was a significant 
correlation between the viral load and percentage total solidsd in the HIV-naïve women. A 
significant correlation also existed between the HIV-naïve women’s CD4 count and total 
breastmilk energy content. Interestingly, there was no correlation between the protein-, 
carbohydrate-, -fat-, calcium- and -phosphate levels and viral load showing that the 
difference could be in other untested components making up the nutritive composition of 
breastmilk.9 
  
                                                          
d
 Total solids are the sum of the protein, carbohydrates, fat and ash/minerals in breastmilk. 
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MOTIVATION FOR THE INVESTIGATION 
Premature delivery is a major global perinatal health problem with a rising incidence in 
Southern Africa.3 African HIV-infected women are more likely to give birth to premature 
infants.3-6 The SA HIV epidemic is regarded as a national health crisis that affects a great 
proportion of the population.11 Statistics show that a third of SA women who attend 
antenatal clinics are HIV infected.12  
Sufficient evidence is available to show that premature infants significantly benefit from 
human breastmilk in the short and long term in a dose-dependent way.76 The American 
Academy of Pediatrics recommends human milk as the preferred feed for all newborns, 
including premature infants.181 Recent PMTCT policy changes14 as well as advancements in 
maternal and neonatal ART regimens proved that the provision of expressed breastmilk 
and/or breastfeeding is safe for the HIV-exposed premature infant.18,19 The side effects of 
ART include adverse effects on metabolic and endocrine systems, such as morphological 
body changes, dyslipidaemia, glucose intolerance and bone mineral abnormalities.25  
Breastmilk composition is highly variable among individuals.86 It is well known that stage of 
lactation,148 foremilk versus hindmilk,71,144 prematurity,81-149 maternal diet144,and 
pasteurisation method179 influence breastmilk composition.  Maternal nutritional status and 
breastmilk expression technique167 do not influence breastmilk composition. Recently, SA 
data showed that there were differences in the breastmilk composition of HIV-infected and 
HIV-uninfected women who had given birth to term9 and preterm infants.10 To date, the 
effects of ART on breastmilk composition are unknown. The aim of this investigation was to 
evaluate the differences in breastmilk composition of HIV-infected women receiving ART 
and HIV-uninfected women. The link between maternal HIV infection and LBW and IUGR is 
controversial in African studies.53-62 The effects of ART on birth outcomes are still 
indefinite.49-51 The objectives of this investigation were to assess the anthropometric 
parameters of HIV-infected and HIV-uninfected mothers as well as to assess the neonatal 
anthropometric parameters of premature infants in relation to maternal anthropometric 
parameters, HIV status and ART regimen. 
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In this chapter, the research methodology will be described. The research question, aim and 
objectives as well as the complete study plan are detailed in the following sections.   
Research Question 
Is there a differce in the breastmilk composition of HIV-infected mothers [receiving 
antiretroviral therapy (ART)] and HIV-uninfected mothers who gave birth to premature 
infants? 
2.1 Aim of the investigation 
The aim of the investigation was to assess and compare the breastmilk composition of HIV-
infected (receiving ART) and uninfected mothers who give birth to premature infants. 
2.2 Objectives of the investigation 
The objectives included the following: 
i. To describe  the HIV-infected mother population with reference to the use of ART 
treatment schedule and disease state 
ii. To compare the breastmilk components of HIV-infected mothers receiving ART, 
according to the ART regime with that of HIV-uninfected mothers  
iii. To assess the anthropometric parameters (weight, height and MUAC) of HIV-infected 
and -uninfected mothers 
iv. To assess  the neonatal anthropometric parameters of the premature infants in 
relation to maternal nutritional status, HIV status and ART regime 
2.3 Null Hypothesis 
HO: There is no difference between the nutritive breastmilk composition of HIV-infected 
mothers receiving ART and -uninfected mothers who gave birth to premature infants.  
HO: Maternal nutritional status, HIV status and ART regime do not affect neonatal nutritional 
status at birth 
Figure 2.1 depicts a conceptual framework to address the aim and objectives of the 
investigation. 





Figure 2.1: Conceptual framework to address the study aim and objectives 


















Stellenbosch University  https://scholar.sun.ac.za
52 
 
2.4 Study Design 
The research entailed a cross-sectional descriptive study with an analytical component. 
2.5 Setting 
The study was conducted in the postnatal paediatric ward(s) of Kalafong Hospital, Pretoria. 
The wards included in the study were the Neonatal High Care and Intensive care unit (ICU) 
and the Kangaroo Mother Care (KMC) Unit.  
2.6 Study population 
The study population consisted of HIV-infected and –uninfected mothers who gave birth to 
premature infants.  The infants of the mothers were also included in the study. 
2.7 Sample size 
The sample size was calculated by a 1-way ANOVA sample size calculation. In order to 
obtain an effect size (RMSEE) = 0.55, the sample size had to include 68 mothers (N=68). The 
four subgroups each had to include 17 mothers (n=17). Thus, the final sample had to include 
17 HIV-infected mothers receiving ART who gave birth to preterm neonates 24-33 weeks 
gestation; 17 HIV-infected mothers receiving ART who gave birth to preterm neonates 34-37 
weeks gestation, 17 HIV-uninfected mothers who gave birth to preterm neonates 24-33 
weeks gestation and 17 HIV-uninfected mothers who gave birth to preterm neonates 34-37 
weeks gestation; (p=0.05). Please refer to schematic diagram Figure 2.2 for a visual 
presentation of the information described here. Table 2.1 depicts the study setting with 
associated statistics (2013). 
Table 2.1: Statistics on breastfeeding mothers at Kalafong Hospital 
Ward Number of breastfeeding mothers per day 
Observation 10 
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The final sample consisted of 74 mother-infant pairs. This included 38 HIV-infected mothers 
and –exposed infants receiving ART; and 36 HIV-uninefected mothers and –unexposed 
infants. A total of 92 pairs were screened for inclusion in the investigation. Seventeen pairs 
did not meet the inclusion criteria of which twelve mothers were discharged before data 
collection procedures were completed, two mothers did not have adequate breastmilk 
volumes to provide a second sample, one mother were not on ART at the time of data 
collection and two mothers were excluded due to an ELISA test not performed. One mother 
declined consent (no questionnaire was filled in). Mothers whose breastmilk production 
were inadequate to provide the full sample over one or two days (methods dicussed in 
section 2.11.2.3) were excluded due to ethical reasons.  Figure 2.2 provides a schematic 
presentation of the sample. A total of 260 infants were admitted during the period of data 
collection.





Figure 2.2: Flow diagram of mother-infant pairs included in the investigation

















1 participant did 
not recieve ART 
74 included in 
final sample 
38 HIV+ on ART 
15 in group 3 
Gestation 33-37 
weeks 




18 in group 1 
Gestation 34-37 
weeks 
18 in group 2 
Gestation 24-33 
weeks 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
55 
 
2.8 Sample Selection 
All mothers and infants pairs who fitted the inclusion criteria and provided written informed 
consent were included in the study.  
2.9 Inclusion Criteria 
The inclusion criteria were as follows:  
I. All mothers who gave birth to live, premature infants (<37 weeks gestation)  and  
who were willing to participate and provide written informed consent 
II. Only mothers who decided to breastfeed after counselling, regardless of their 
HIV status, were included. (All HIV-infected mothers are counselled routinely at 
Kalafong  Hospital about the risks and benefits of breastfeeding and bottle-
feeding relating to the prevention of mother to child transmission (PMTCT) 
programme) 
III. HIV-infected mothers who were on the (PMTCT) treatment regimen and if 
antiretroviral (ARV) medication was prescribed  
IV. Premature infants 24-33 and 34-37 weeks gestation 
V. First born infant of twins 
2.10 Exclusion Criteria 
All lactating mothers: 
I. Who gave birth to premature infants <500g or <24 weeks gestational age 
II. Who was breastfeeding infants/children from a previous pregnancy  
III. Whose infants did not have a completed Road to Health Booklet available or 
who’s medical information were incomplete or unavailable  
IV. Who were unable to provide adequate quantities of breastmilk after feeding her 
infant(s) 
V. Who were known for substance abuse 
VI. With active Mycobacterium tuberculosis who were still potentially infectious  
VII. Who were receiving medication that are contra-indicated during lactation (Table 
2.2) 
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Table 2.2: Medication contra-indicated during lactation1    
Classification Drugs 
Psychiatric therapy Antipsychotics (chlorpromazine, lithium), 




Cyclophosphamide, Doxorubicin, Methotrexate, Gold salts, 
Propylthiouracil, Methimazole 
*Cyclosporine is safe for lactation 
Antineoplastic therapy Cisplatin, cyclophosphamide, methotrexate, doxorubicin 
Anticonvulsants Phenobarbital, ethosuximide, 
primidone 
Drugs of abuse Ethanol, amphetamines, opioids, phencyclidine 
Ergot-alkaloids Ergonovine, bromocriptine 
Other Radiopharmaceuticals, chloramphinicol, phenylbutazone, 
atropine, thiouracil, iodides, mercurals, warfarin, 
cytotoxics, amiodarone, estrogen-containing 
contraceptives, diuretics  
  
2.11 Data Collection 
2.11.1 Subject recruitment 
Consecutive mother-infant pairs were included in the study. This included 38 HIV-infected 
mothers and –exposed infants receiving ART; and 36 HIV-uninefected mothers and –
unexposed infants. The subjects were identified by the medical staff and verified by the 
most senior clinician. Staff (paediatricians, doctors and nurses) notified the primary 
researcher of admissions and possible candidates. On weekdays, the primary researcher 
attended the facility in the afternoons on a daily basis.  
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2.11.2 Maternal Information  
2.11.2.1 Establishing HIV status 
An HIV-infected status was established by a confirmed positive rapid HIV test during the 
prenatal period and an -HIV-uninfected status was confirmed with an ELISA test in the 
postnatal period.  
The researcher ensured that all mothers provided accurate information regarding ART 
regimes and dosages by checking prescription charts (from hospital file and/or antenatal 
file) or asked the mothers to show her their home medication. 
2.11.2.2 Questionnaire 
A researcher-administrated demographic questionnaire, tested for face and content validity, 
was completed. A pilot study was conducted to ensure face validity of the questionnaire. 
The questionnaire was also reviewed by two experts in the field of paediatrics and HIV. All 
staff involved in the data collection was trained to standardise methods. Refer to Addendum 
A. 
2.11.2.3 Breast milk sample collection  
Samples of HIV-infected and HIV-uninfected breast milk were analysed. All breast milk 
samples were raw untreated specimens; therefore milk samples did not undergo any 
pasteurization procedures. Lactation consultants/ milk handlerse were responsible for 
sample collection, coding and freezing of samples. Samples were frozen immediately upon 
collection. The researcher communicated information regarding participants and dates of 
sample collection to the lactation consultants. 
Breast milk was collected in sterilised containers with lids. Expression of breast milk was 
done by hand. Participants washed their hands prior to expression as per ward protocol.  
Two milk samples were collected from each mother on the following days:  
i. Milk sample 1 (Macronutrient Analysis) 
The first milk sample was collected on day seven of lactation; 
                                                          
e
 Lactation consultants/ milk handlers: on-site personnel responsible for breastfeeding support and 
organisation of the on-site Human Milk Bank. 
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ii. Milk sample 2 (Micronutrient Analysis) 
The second milk sample was collected on day nine of lactation. 
Each sample contained a volume of 30-40ml of expressed breast milk for the analysis.  
Samples were collected after mothers expressed milk/ breastfed for her infant(s). 
Mothers unable to provide the full sample (30-40ml) were asked to give 15ml on two 
consequtive days (i.e. 15ml on day seven and 15ml on day eight; or 15ml on day nine and 
15ml on day ten of lactation). Refer to Figure 2.3 for a schematisation of the data collection 
procedures. 
All milk samples were collected by the investigator or research assistant. Milk samples were 
stored at -20⁰C immediately after collection. Frozen samples were transported to the 
laboratories in a sealed cooler directly after removal from the freezer.  The laboratories that 
performed the analysis included: Lactolab (Pty) Ltd (analysis of the macronutrients) and the 
Agricultural Research Council (ARC) Irene Analytical Services (analysis of the micronutrients). 
The following nutritive components were analysed: total energy, carbohydrates, protein, 
lipids, phosphorus, iron, zinc and copper.  The determination of macronutrients (lactose, 
protein and lipids) was done by means of infrared analysis (IDF 141B: 1996) with Bentley 
Fourier Transform Spectrometer (FTS) based on Fourier Transform Infrared Spectrometry 
Technology. The analyses were done according to international standards organisation (ISO) 
reference standards (described in section 2.13.1). Total carbohydrates were calculated by 
subtracting the protein and fat from the total solids. Thus: total carbohydrates (g) = total 
solids (g) – protein (g) – fat (g). The total energy of each sample was calculated by the 
following equation:  
Total energy (kCal/100ml) = 
𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑥 17
4.2
 + 
𝑔 𝑐𝑎𝑟𝑏𝑜ℎ𝑦𝑑𝑟𝑎𝑡𝑒𝑠 𝑥 17
4.2
 +
𝑔 𝑓𝑎𝑡 𝑥 38
4.2
 
The analysis of the micronutrients (phosphorus, iron, zinc and copper) was done by 
Inductively Coupled Plasma Optical Emission Spectrometer (ICP-OES). Each sample was 
analysed three times whereupon the average was used.  
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Rationale behind breastmilk sample collection 
Sampling was conducted on day seven and nine of lactation to ensure that lactation/ 
breastmilk production was established. Because breastmilk production is low in women who 
gave birth to premature infants, collection was done two days apart. Mothers who were not 
able to provide the full volume had the option of giving the full volume over two 
consecutive days per sample. Refer to Figure 2.3 for a schematic presentation of data 
collection procedures. The micronutrients selected for analyses (phosphorus, iron, zinc and 
copper) were selected for their role in growth and development and has been shown to be 
of the major minerals that are low in preterm infants. Refer to section 1.8.7 for a complete 
description of the importance of each mineral in the nutritional care of the preterm infant. 
 
Figure 2.3: Schematic presentation of data collection procudures 
2.11.2.4 Maternal anthropometry 
Maternal anthropometric data [weight, height and mid-upper arm circumference (MUAC)] 
was collected on day seven after giving birth. Measurements were standardised and 
conducted according to the WHO Universal Standards.2  Body Mass Index (BMI) was 
calculated according to the standard method, i.e. BMI (kg/m2) = 
weight
ℎ𝑒𝑖𝑔ℎ𝑡2




Breastmilk sample 1: Day 7 
• Sample 1 (30-40ml OR 2x 15-20ml) 
• Macronutrients 
• Protein, carbohydrates, fat 
• Analyses at Lactolab 
Breastmilk sample 2: Day 9 
• Sample 2 (30-40ml OR 2x 15-20ml) 
• Micronutrients 
• Phosphate, iron, zinc, copper 
• Analyses at ARC Irene 
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The following methods were used: 
Weight: 
A portable, electronic calibrated scale was used to conduct the measurements. Weight 
measurements were rounded off to the nearest 100g and were determined as follows:2  
i. The participant had to be wearing minimal clothing with her shoes taken 
off 
ii. Participant stood upright on the scale looking forward 
iii. The participant did not have support to stand 
iv. Weight was read  
v. Participant stepped off the scale 
vi. Procedure was repeated three times and an  average value was calculated 
 
Height: 
A portable measuring stick (stadiometer) was used for height measurements. Height 
measurements wererounded off to the nearest 1mm and were determined as follows:2 
i. The participant stood barefoot on the  ground with feet shoulder with 
apart and heels touching the back panel 
ii. All head gear had been removed  
iii. The participant stood upright with the spine and pelvis and shoulder level 
should touch the upright 
iv. Shoulders were relaxed and arms hung at the sides 
v. The measuring stick was lowered onto the participant’s head and the 
measurement was taken with inhalation 




A measuring tape was used to conduct the measurements. All measurements were rounded 
off to the nearest 1mm and was determined as follows:2 
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i. The participant stood upright with hands hanging loosely at sides 
ii. Feet were shoulder width apart 
iii. The participant was asked to bend her right arm in a 90˚ angle with the 
palm facing upward 
iv. The distance between the acronium and olecranum was measured and 
the midpoint was found 
v. The participant was asked to relax her arm and to let it hang loosely at 
her side 
vi. The midarm circumference was measured by ensuring the measuring 
tape was parallel to the ground  
vii. It should not have been too loose and should not have cut into the 
participants’ skin 
viii. The measurement  was taken three times and the average measurement 
was calculated 
2.11.3 Neonatal information 
2.11.3.1 Establishing the gestational age 
If the mother had not had an early sonar during pregnancy, gestational age was determined 
by the Ballard Score.f [This method is used in the research setting (Kalafong Neonatal Unit) 
as early sonars are rarely available or adhered to.] The Ballard score was done at birth and 
repeated (checked) the first day when the most senior clinician was available. The Ballard 
score is accurate for the first five days of life. Thus, infants born over a weekend was scored 
on the first weekday after birth. 
2.11.3.2 Neonatal anthropometric data 
Neonatal anthropometric data [birthweight, recumbent length and head circumference 
(HC)] at birth was noted. The measurements were repeated according to standardised 
methods2 to ascertain accuracy. Intra-uterine growth restriction was classified according to 
the Fenton growth chart for premature infants.3 
 
                                                          
f
 Ballard Score: Technique to determine the gestational age of neonates whereby a score is assigned to various 
criteria. The sum of all scores is used to determine the gestational age. Criteria is devided into physical and 
neurological development areas. 




The weight of each infant was determined as follows:2 
i. An electric scale was used, with an accuracy of 0.001kg;  
ii. All instruments were zero calibrated before commencing with the measurements; 
iii. Infants were weighed without any clothing or a nappy. If a nappy was worn, the 
weight was corrected by subtracting the weight of the nappy; 
iv. Infants were placed in the middle of the scale and the baby had to lie still before the 
reading was taken; 
v. The measurements were read to the nearest 0.001kg; and 
vi. The average of three measurements was reported.  
 
Head circumference 
Head circumference was taken with a standard measuring tape. Measurements were 
rounded off the nearest millimetre and conducted according to the following method.2 
i. All head gear were removed 
ii. The measuring tape was wrapped around the widest part of the infant’s head 
from the most prominent part of the head (approximately 1-2 fingers above 
the eye brows) to the point of the occipital bone (occipital bun) 




Length was measured with a portable, length board. Two persons were needed to do the 
measurement. All clothing were removed. The following procedures were used:2 
i. The infant was positioned with head touching the board. The infant was lying 
in a straight line. The Frankfort plane was perpendicular to the board. One 
person stood behind the infant’s head and held the infant straight. 
ii. The second person stood next to the infant and hold the movable foot piece 
in his/her right hand. The infant’s body was positioned so that the shoulders, 
back and buttocks were flat along the centre of the board. The infant’s knees 
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were pushed down so that the legs were straight and flat against the centre 
of the board. The foot piece was brought to the infant’s heel that formed a 90 
degrees angle with the board. 
iii. Measurements were repeated three times and the average measurement 
was recorded. 
 
2.12 Data Handling And Analysis 
2.12.1 Laboratory techniques to analyse breastmilk samples 
2.12.1.1 Macronutrients 
i. Protein 
The protein content of breastmilk was determined by measuring the absolute nitrogen 
content and then using a formula to calculate the total protein content. ISO 8968/ IDF 20 
standards were used. The principle behind the procedure is to digest a part of the test 
proportion by using a block-digestion apparatus with a mixture of sulphuric acid and 
potassium sulphate and copper suphate as a catalyst to convert organic nitrogen to 
ammonium sulphate.4 Analysis procedures were as follows:  
i. The test sample was prepared: Test sample was warmed in a water bath at 38°C. The 
test sample was mixed thoroughly by repeatedly inverting the test sample without 
frothing. The sample was cooled to room temperature before weighing. 
ii. Procedure: 12g potassium sulphate, 1ml copper sulphate solution, 20ml sulphuric 
acid and 5ml of the prepared sample was added to the clean digestion tube. The 
solution was then mixed. 
iii. Digestion: The digestion block was set at a low temperature (180- 230°C) to avoid 
foaming. The tube was transferred to the digestion block which was connected to a 
centrifuge. The rate of the centrifuge should have been sufficient to remove excess 
fumes. The mixture was digested for 30 minutes or until white fumes had developed. 
The process was continued until the solution was clear. The tube was removed from 
the block with the exaust manifold in place. The tube was cooled down to room 
temperature over approximately 25 minutes. The cooled down solution was liquid 
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with a few crystals at the bottom. 85ml of water was added. The test tube was 
swirled so that all crystals dissolved.  
iv. Distillation: The condenser water for the apparatus was switched on. The digestion 
tube was attached to the distillation apparatus. A flask was positioned with 50ml 
boric acid under the the condenser. The steam distill method was used and 150ml of 
the solution was collected. The flask was removed from the distillation apparatus. 
v. Titration: The contents of the flask with the hydrochloric acid that formed during the 
distillation phase using a burett was titrated. The process was completed when the 
first traces of pink contents were distinguished. The reading was estimated to the 
nearest 0.05ml. 
vi. The nitrogen content to the nearest four decimal places was calculated. 
vii. The prude protein content was calculated and the the results were expressed to the 
nearest four decimal places. 
ii) Lactose 
Lactose content was determined by using the international standard: ISO 22662 /IDF 198 
(2007).5 The procedures were as follow: 
i. Preparation of the sample: The test sample was warmed in a water bath between 38 
and 40°C. The test sample was mized by inverting it gently and cooled down to 21°C. 
ii. Preparation of the standard solution: The appropriate amount of α-lactose 
monohydrate was weighed down to give 20mg/ml anhydrous α-lactose solution. The 
α-lactose monohydrate was then dissolved in 5ml High Performance Liquid 
Chromatography (HPLC) grade water. Added to this was 2ml of melezitose and mixed 
gently. The final α-lactose content was expressed in mg/ml. The solultion was 
filtered through filter paper using a filter tunnel. The filtrate was then apsirated into 
a syringe. 
iii. Preparation of the test solution: The prepared test sample was weighed to the 
nearest 1mg into a 10ml volumetric flask and 5ml of the HPLC water that was 
prewarmed between 50 and 60°C was added. The solution was mixed until it 
presented homogenous. It was allowed to cool down to 20°C. 
iv. Prepare the filtrate: 2ml of the melezitose solution and 1.2ml of Biggs-Szijardo 
solution was added to the contents of the flask. It was mixed by gently inverting the 
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flask five times and then allowed to cool to room temperature for 10 minutes. The 
mixture was filtered by using fliter paper then the mixture was transfered into a 
HPLC vial. 
v. HPLC determination: The detector was turned on at least 24 hours before the 
analyses. The internal temperature was set at 35.5°C and the flow rate of the HPLC 
water pump was controlled to 0.2ml/min for at least 20min while the column heater 
was set to room temperature. The latter was heated to 85°C then gradually 
increased to a flow rate to 0.6ml/min. Chromatographic conditions was strictly 
adhered to. 
vi. Calculations: Calculations were done by computer software which generated the 
lactose content as a curve by plotting the response ratio of lactose to a standard 
peak area. The software devided the concentration derived from the curve by the 
mass of the test sample to calculate the lactose mass as a fraction, expressed as a 
percentage.  
iii) Fat 
Fat content was determined by gravimetric analysesg according to ISO 1211:2010(E) 
standards.6 The steps followed in the analyses are described below: 
i. Prepared the test sample: Using a warm waterbath, the test sample was warmed to 
a temperature of 38°C. If a homogenous sample was obtained, without prior 
warming, the test sample was brought to a temperature of 20°C. 
ii. Test portion: The test sample was mixed by gently inverting the bottle three to four 
times and immediately weighed to the nearest mg, 10-11g of the sample directly or 
indirectly into a fat-extraction flask. 
iii. Prepared a blank test (control): A blank test was carried out simultaneously with the 
determination by using the same reagents. 
iv. Prepared the fat-collecting vessel: The fat-collection vessel was dried with a few 
boiling aids in the oven at 102°C for 1 hour and then allowed to cool down in a metal 
container for 30 minutes. The fat collecting vessel was weighed to the nearest 1mg. 
                                                          
g
 Gravimetric analysis describes a set of methods in analytical chemistry for the quantitative determination of 
an analyte based on the mass of a solid. A simple example is the measurement of solids suspended in a water 
sample: A known volume of water isfiltered, and the collected solids are weighed. 
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v. Determination: 2ml ammonia, 10ml ethanol and 25ml diethyl ether were added to 
the vessel and mixed well. The mixture was closed with a cork and shaken vigorously 
to prevent the formation of emulsions. 25ml of light petroleum was added and 
mixed for 30 seconds. The mixture was centrifuged for 1-5 minutes at a radial 
acceleration of 80-90g. The cork was removed and the mixture was then decanted 
into the previously prepared fat-collection vessel. The fat-collection vessel was 
heated to 102°C in an oven for 1h to dry. It was then removed from the heat and 
immediately verifed if the fat emultion was clear. Finally the mixture was allowed to 
cool to room temperature.   
vi. Calculation: The content of the fat in the sample was calculated and expressed as a 
percentage mass fraction. 
2.12.1.2 Micronutrients  
The following micronutrients were analysed: phosphate, iron, zinc and copper by means of 
the following procedure: 
i. Sample Preparation: 
For the first 2 batches of milk samples (batch 2014-F-465, samples 1 to 25 and batch 2014-F-
544, 29 samples from sample 026 to 064 with several gaps in the sample numbering) the 
liquid samples were digested and analysed directly with no initial sample preparation, just 
storage in a fridge. The third batch (batch 2015-F-117, samples 1 to 28) was freeze dried and 
milled by a different laboratory (ARC-Irene) to convert the liquid milk samples into milk 
powder samples. The milk samples were weighed before and after freeze drying to calculate 
the amount of water lost and the dry matter content of the liquid milk samples. The water 
or dry matter content values were used by ARC-Irene to convert the values for each element 
from the milk powder samples back to the original liquid milk samples. 
ii. Method for Perchloric and Nitric Acid Sample Digestion: 
For the third batch, 0.5 g of milk powder sample was weighed off. For the first 2 batches, 
between 1.8 g and 4.4 g liquid sample was weighed off (see comment on masses below). 
The samples were digested with 7ml HNO3 (conc. nitric acid) and 3ml HClO4 (perchloric acid) 
at temperatures up to 180C and brought to volume in a 100ml vol. flask. All samples were 
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digested in at least duplicate, mainly triplicate and for batch one some of the samples in 
quadruplicate.7 
 
iii. ICP-OES Determination of P, Zn, Fe & Cu: 
An aliquot of the digest solution is used for the ICP-OES (Inductively Coupled Plasma Optical 
Emission Spectrometric) determination of P, Fe, Zn & Cu. The ICP-OES is a multi-element 
instrument. The instrument used (Varian Liberty Series II) is a sequential instrument, where 
the elements are determined almost simultaneously, with only a few seconds between each 
element. Each element is measured at an appropriate emission wavelength, chosen for high 
sensitivity and lack of spectral interferences. The wavelengths used were: P:213.618nm; 
Fe:259.94nm; Zn:213.856nm & Cu:324.754nm.  Background correction was used for three of 
the elements, P, Fe & Cu, but unnecessary for Zn (low background and stronger signal for 
Zn). 
 
The instrument is set up and operated according to the recommended procedures in the 
instrument manual. It is calibrated against a series of standard solutions, containing all the 
elements of interest in the proportions found in typical leaf samples. (Unpublished method 
developed by Mike Philpott at ARC-ISCW, based on the recommended procedures in the 
instrument manual.8 
 
2.12.2 Demographic, medical, clinical and nutritional data 
The demographic, medical, clinical and nutritional data were captured on a data collection 
form.Refer to Addendum A. The data collection form consisted of three sections:  
i. Section 1 
Information on demographics, obstetric history, breastfeeding history, HIV-status, 
treatment regimen and stage of disease of mother and infant. Refer to table 2.3 for 
information collected in section 1 of the information set. 
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Table 2.3: Information collected in section 1 




Number of people in household 
Obstetric Gestational age 
Gravida/ Para 
Multiparous pregnancy 
Previous premature deliveries 
Breastfeeding history History 
Problems 
Maternal HIV information HIV status 
CD4 count 
Treatment regimen 
Period of ART 
 
Neonatal HIV information HIV exposed 
ART 
 
ii. Section 2 
Information on medical history, current medical problems and medication (including 
ART) as well as clinical notes relevant to the investigation. In this part of the information 
form, spaces were provided for the researcher to note relevant information from the 
hospital file. Blood results and side room observations (vital signs, input-output charts) 
were noted where relevant.  
iii. Section 3 
 Information on maternal and neonatal anthropometric measurements. 
Refer to table 2.4 for information obtained from this section. 
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Table 2.4: Maternal and neonatal anthropometric information obtained from section 3: 








iv. Section 4 
To control/ensure all breastmilk samples were collected. A table was created for the 
researcher to evaluate if samples were collected to stipulated dates. 
2.12.3 Classification of breastmilk composition 
The absolute values of breastmilk composition were compared to results from other studies. 
Refer to table 1.3. The table was adapted from: Koletzko B,9 Anderson DM et al,10 Bishara R 
et al,11 Bauer J, Gerss J,12 Kim SJ et al,13 Ronayne de Ferrer PA et al,14 Tsang RC et al.15 
2.12.4 Classifications of ART period 
HIV-infected women on ART were classified according length of ART treatment. The 
National Consolidated Guidelines for the PMTCT of HIV states that HIV Testing and 
Counselling (HTC) should be done in three or more months before birth16 (assuming the 
infant will be born at term). Since the gestation period is interrupted in premature births, 
this guideline cannot be extrapolated to mothers who gave birth to premature infants. 
Therefore, the classification was setting specific, based on normal tendencies. The infants of 
mothers who received less than 4 weeks of ART were given donor breastmilk for the first 4 
week of life. 
i. < 4 weeks ART exposure  
It is standard practice in the neonatal units of Kalafong Hospital to provide infants 
whose mothers received <4 weeks ART with donor breastmilk to avoid possible 
MTCT of HIV. In light of this, this period was classified as an insufficient treatment 
period. 
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ii. 4-20 weeks ART exposure 
iii. >20 weeks ART exposure 
 
2.12.5 Classification of nutritional status 
2.12.5.1 Maternal nutritional status 
Maternal undernutrition was defined as a BMI <20.3kg/m2, height <1.5m2 or MUAC <5th 
percentile.17 Currently there is no data to classify BMI of mothers who gave birth to 
premature infants.The WHO classification of an adequate nutritional status is a BMI of 20.3 
kg/m2 one month postpartum.17 The researcher chose to use a maternal BMI of ≥20.3 kg/m2 
at birth as an indicator of an normal nutritional status, according to the WHO guidline. 
 
BMI is an inaccurate parameter of nutritional status during pregnancy and lactation. MUAC 
is a potential indicator of nutritional status.18 A normal nutritional status was defined as 
MUAC 5-85th percentile. Overnutrition was defined as a MUAC >85th percentile. 
Measurements were plotted on the Centre of Disease Control and Prevention National 
Centre of Health Statistics’ percentiles.19 Refer to Addendum E. 
 
2.12.5.2 Neonatal nutritional status 
IUGR was classified as a weight-for-age, length-for-age or HC-for-age <10th percentile on 
Fenton growth chart.2 Refer to Addendum F. 
 
2.13 Pilot Study 
A pilot study was conducted to streamline all data collection procedures. All samples were 
collected during this period. Ten mother-infant pairs were recruited for a two-week period. 
Since the protocol was not affected or changed during the pilot study period, it was decided 
that the data collected in the pilot study could be used in the main study. 
2.14 Data Capturing 
Data was captured on Microsoft Excel 2013®. 
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2.15 Statistical Analysis 
Data captured on Microsoft Excel 2013® was exported to Statistica version 12 (StatSoft Inc. 
[2015] STATISTICA [data analysis software system], www.statsoft.com) for data analysis. 
Statistical analysis was done with the assistance of Tygerberg Biostatistics Unit, Stellenbosch 
University. Descriptive statistics were used to investigate the demographics, anthropometry 
and breastmilk nutritive composition of participants. When groups were compared, 
repeated measures of analysis of variance (ANOVA) and t-tests were used.  
Confidence Intervals were determined in the analyses of data. A p-value of p<0.05 was used 
to indicate a significant difference between groups.  
2.16 Financial Disclosure 
The investigation received funding from the Harry Crossley Foundation, administered by 
Stellenbosch University. 
2.17 Ethics Approval 
The study was granted written Ethics Approval from the Human Research Ethics Committee 
of Stellenbosch University (S13/09/165) and the Research Ethics Committee of the Faculty 
of Health Sciences at the University of Pretoria (191/2014). Guidelines for Applied Good 
Clinical Practice were adhered to at all times. The primary researcher completed the course 
for Applied Good Clinical Practice. 
Participants were informed about the investigation in a language that they were fluent in 
and mothers received adequate time to consider participating. (Mother-infant pairs were 
identified at birth of the infant and mothers had seven days from birth to provide the first 
milk sample and to consider consent.) Written informed consent forms were available in 
Tswana, English and Afrikaans. (Refer to Addenda B-D). A copy was given to each mother to 
keep for her records. 
It was considered standard medical care to conduct an ELISA test on all -uninfected 
mothers, however mothers had to provide verbal consent. Medical personnel who 
performed the test provided counselling as per usual protocol. Mothers who could not 
provide adequate volumes of breastmilk were not pressured to participate. No feeds were 
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withheld from infants. The sample volume of 30ml was stipulated as a minimum volume to 
analyse the samples by the laboratories.  
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The results section is reported in two separate articles. A degree of unavoidable overlap 
occurs between the information and data reported in the articles and the previous chapter. 
The articles will be submitted for publication to relevant peer reviewed journals. 
 
3.1 ARTICLE 1 
Differences in Breastmilk Composition of HIV-Infected and HIV-uninfected mothers of 
Premature Infants: Effects of Antiretroviral Therapy 
3.2 ARTICLE 2 
Anthropometric Parameters of HIV-Infected and HIV-Non Infected Mothers and their 
Premature Infants. 
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A key strategy to prevent mother-to-child-transmission (MTCT) of the human 
immunodeficiency virus (HIV) and to reduce infant morbidity and mortality includes 
providing the HIV-exposed premature infant with breastmilk accompanied by maternal and 
infantile anti-retroviral therapy (ART). The effects of HIV and ART on premature breastmilk 
composition are largely unknown. The aim of the study was to assess and compare the 
breastmilk composition of HIV-infected mothers receiving ART and HIV-uninfected mothers 
who gave birth to premature infants.  
Lactating HIV-infected women receiving ART (n=38) and HIV-uninfected women (n=36) who 
gave birth to premature infants were enrolled in the study. Mothers provided two 
breastmilk samples on day seven and nine of lactation. Breastmilk samples were analysed 
for total energy, protein, carbohydrates, fat, phosphate, iron, zinc and copper content.  
Breastmilk of HIV-infected women contained higher protein (1.95 vs. 1.78 g/100g; p=0.04), 
fat (4.42 vs. 3.49 g/100g; p=0.01) and copper (0.64 vs. 0.56 mg/l; p=0.02) levels while 
carbohydrate (5.37 vs. 6.67 g/100g; p=0.002) and zinc (5.26 vs. 5.78 mg/l; p=0.04) levels 
were lower compared to those of HIV-uninfected women. Zinc levels were significantly 
lower in HIV-infected women with early gestation periods and the lowest levels were 
obeserved in women who received ART for ≤4 weeks (0.58mg/l; p=0.03). Total energy 
(78.22 vs. 61.48 kCal/100ml) and fat levels (5.39 vs. 3.00g/100ml) were significantly higher 
in the late gestation period HIV-infected women. Copper levels (0.61mg/l) were higher in 
late gestation period women who received >4 weeks ART exposure (p=0.05).  
In this study differences existed in the breastmilk composition of HIV-infected women on 
ART compared to HIV-uninfected women. ART exposure period may influence breastmilk 
composition.  
Keywords:  Breastmilk, Human Immunodeficiency Virus (HIV) Antiretroviral Therapy (ART), 








The heavy burden of maternal human immunodeficiency virus (HIV) infection is established 
in literature (Murry 2014, UNAIDS 2015, WHO 2015). As treatment has evolved into regimes 
of highly active antiretroviral therapy (HAART) the prevalence of low birth weight (LBW) and 
preterm birth among infants born to HIV-infected women has increased in developing 
countries (Watts 2013, van der Merwe 2011, Powis 2011, Kourtis 2007, Suy 2006).  
 
It is well known that ART exhibit adverse outcomes in metabolic and endocrine systems in 
HIV-infected people. This includes dyslipidaemia, glucose intolerance and bone 
mineralisation abnormalities (Anuurad 2009, Da Cunha 2015, Abdollahli 2014, Riddler 2003). 
The effects of ART on breastmilk composition are however, unknown.  
Proven to reduce morbidity and mortality, breastmilk is the recommended form of enteral 
nutrition for premature and LBW infants. Premature breastmilk composition is influenced by 
various factors which include: stage of lactation (Bauer 2011, Neville 1984, Bitman 1983, 
Emery 1978, Ogechi 2013), duration of lactation (Gidrewicz 2014, Hsu 2014, Luukkainen 
1994), length of gestation (Brown 2008, Bokor 2007) and HIV-infection (van der Heever 
2014). Limited data is available on the breastmilk composition of HIV-infected mothers who 
gave birth to preterm infants. Furthermore, no data is available regarding the effects of ART 
on breastmilk composition. A recent South African study found significantly higher protein 
and lower calcium levels in breastmilk samples of HIV-infected mothers when compared to 
HIV-uninfected mothers who gave birth to term infants (van der Heever 2014). The aim of 
this study was to assess and compare the breastmilk composition of HIV-infected mothers 
(receiving ART) and uninfected mothers who give birth to premature infants. 
Materials and Methods 
A cross-sectional descriptive study with an analytical component was conducted from the 
period August 2014 to April 2015 in the Neonatal Units of Kalafong Hospital, Pretoria, South 
Africa. Consecutive sampling was used to recruit participants. The study population 
comprised of postnatal lactating HIV-infected mothers receiving ART- and HIV-uninfected 
mothers who gave birth to premature infants. All mothers received accommodation at the 
unit as per standard protocol. The sample size determination was based on data of live 
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births from the institution. The sample size was calculated by a 1-way ANOVA calculation to 
obtain an effect size (RMSEE) = 0.55. 
An HIV positive status was established by routine confirmed positive rapid HIV testing 
during the prenatal period and an HIV negative status was confirmed with routine ELISA 
testing in the postnatal period.  The HIV-infected women were divided into three groups 
according to period of ART exposure: 1) <4 weeks of ART, 2) 4-20 weeks of ART and 3) >20 
weeks of ART. It is practice in the unit to provide neonates whose mothers initiated ART at 
birth with donor breastmilk for the first 3-4 weeks. In light of this, a maternal ART exposure 
<4 weeks was classified as insufficient ART exposure and ≥4 weeks as sufficient ART 
exposure. Gestational age was estimated by using the Ballard score as early sonars are 
rarely performed. Premature infants born between 24-33 weeks gestation and 34-37 weeks 
gestation will be referred to as early- and late gestation periods respectively. Standard 
medical treatment was continued during the study period.  
A researcher-administrated demographic questionnaire, tested for face and content validity 
during a pilot project, was completed. All personnel involved in the data collection were 
trained and standardised by the principal investigator.  
Two breastmilk samples were collected from each mother. Breastmilk samples were 
collected on day seven and day nine of lactation for macronutrient and micronutrient 
analyses, respectively. Mothers expressed breastmilk with the manual expression 
technique. Thereafter, raw, untreated breastmilk samples were frozen at -20°C immediately 
after collection and transported to the Lactolab and Agricultural Research Council 
laboratories for macro-and micronutrient analyses, respectively.  
The following nutritive components were analysed: total solids, ash, protein, carbohydrates, 
lipids, phosphorus, iron, zinc and copper. The determination of macronutrients (lactose, 
protein and fat) was done by means of infrared analysis (IDF 141B: 1996) with Bentley 
Fourier transform spectrometer (FTS) based on fourier transform infrared spectrometry 
technology (Griffiths 2007) according to international standards organisation (ISO) 
standards (ISO 2001, ISO 2007, ISO 2010). Total carbohydrates were determined by 
subtracting the determined protein and fat from the total solids. Total energy was 
calculated by adding the energy contributions of protein, carbohydrates and lipids. The 
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analysis of the micronutrients was done with inductively coupled plasma optical emission 
spectrometer (ICP-OES) (Boss 1997). Micronutrients, specifically those of importance in 
growth and antioxidant defences for premature infants, were selected for analysis. 
Data captured on Microsoft Excel 2013® was exported to Statistica version 12 (StatSoft Inc. 
[2015] STATISTICA [data analysis software system], www.statsoft.com) for data analysis by 
the Tygerberg Biostatistics Unit, Stellenbosch University. Descriptive statistics were used to 
present the demographic characteristics of participants. When groups were compared, t-
tests, ANOVA, Mann Whitney and Kruskal Wallis tests were used. The Bonferroni correlation 
test was performed when several dependent- or independent factors were analysed. 
Statistical significance was defined as p<0.05. 
The study was granted ethics approval from the Human Research Ethics Committee of 
Stellenbosch University (S13/09/165) and the Research Ethics Committee of the Faculty of 
Health Sciences at the University of Pretoria (191/2014). The study was conducted in 
accordance with Good Clinical Practice Guidelines.  
Results 
A total of 92 pairs were screened for inclusion in the investigation. Seventeen pairs were 
excluded of which twelve mothers were discharged before data collection procedures were 
completed, two mothers did not have adequate breastmilk volumes to provide a second 
sample, one mother was not on ART at the time of data collection and two mothers were 
excluded due to an ELISA not performed. One mother declined consent.  The final sample 
consisted of 74 mother-infant pairs. This included 38 HIV-infected mothers and –exposed 
infants receiving ART; and 36 HIV-uninefected mothers and –unexposed infants. There were 
no significant differences between HIV-infected and HIV-uninfected women with respect to 
age, gestation period, ethnicity and education level (Table 1). The mean maternal age was 
27.86 years (SD±5.57) and the mean gestation period was 32.08 weeks (SD±3.03). The 
majority (73.99%) of the participants were African women.  Of the 74 participants, 38 (51%) 
were HIV-infected on ART and 36 (49%) were HIV-uninfected. All HIV-infected women 
received a fixed dose combination (FDC) ART which is a combination of tenofovir, 
emtricitabine and efavirenz (National Department of Health, South Africa 2014). Seven of 
the HIV-infected mothers (18%) received insufficient ART treatment for <4 weeks prior to 
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labour and 31 mothers (82%) were administered ART for >4 weeks. Of these, 13 mothers 
(34%) received treatment for 4-20 weeks and 18 mothers (47%) received treatment for >20 
weeks. The period of ART ranged from one day to seven years with a mean period of 8.9 
months (SD=15.4). In this group, the CD4 count ranged from 51-720 cells/mm
3 with a mean 
CD4 count of 367 (SD=165) cells/mm
3. No significant differences were found between 
gestational periods and ART duration (p=0.99 and p=1.00 respectively). 
HIV-status and ART duration in relation to breastmilk composition 
Breastmilk of HIV-infected women contained significantly higher protein (1.95 vs. 1.78 
g/100g; p=0.04), fat (4.42 vs. 3.49 g/100g; p=0.01) and copper (0.64 vs. 0.56 mg/l; p=0.02) 
levels compared to HIV-uninfected women. The carbohydrate (5.37 vs. 6.67 g/100g; 
p=0.002) and zinc (5.26 vs. 5.78 mg/l; p=0.04) levels were significantly lower in HIV-infected 
women compared to HIV-uninfected women (Table 2). Differences were not detected in 
total energy, phosphate and iron levels with respect to HIV-status. The ART period did not 
affect the breastmilk composition (Supplementary material, Table 1). 
HIV-status and gestation period in relation to breastmilk composition 
Previous research had indicated that length of gestation significantly influences breastmilk 
composition (Gidrewicz 2014, Hsu 2014, Luukkainen 1994). Therefore, results were also 
analysed according to gestation period. Lower zinc levels were found in the early gestational 
age category (24-33weeks) with respect to HIV-exposure status (Supplementary material, 
Table 2). Lower zinc levels were observed in early gestation period HIV-infected mothers 
who received ART exposure for ≤4 weeks (p=0.03) (Figure 1). Total energy (78.22 vs. 61.48 
kCal/100ml) and fat (5.39 vs. 3.00g/100ml) levels of late gestational age categories were 
significantly higher in breastmilk samples of women with insufficient ART compared to 
samples from HIV-uninfected women. Copper levels (0.61mg/l) were higher in women with 
late gestation who received 4 – 20 weeks treatment compared to HIV-uninfected women on 








Early recognition of HIV-infection is a key strategy in decreasing mother to child 
transmission. Even though no significant differences were found between gestational 
periods and ART duration it is evident that the current PMTCT programme is effective when 
comparing the mean ART treatment period and mean gestation periods.  
Our results confirm data from a previous study conducted in South Africa that reported 
protein elevation in breastmilk of HIV-infected mothers of term infants. Furthermore, when 
they categorised the HIV-infected women into groups receiving ART and not, no statistical 
differences existed for all nutrients analysed (van der Heever 2014). 
The effect of gestation period (prematurity), HIV-status and length of ART exposure on 
breastmilk composition presented intriguing results. When the sample was subdivided 
according to HIV status, the HIV-infected group receiving ART had significantly higher 
breastmilk protein, fat and copper levels, while carbohydrates and zinc levels were lower. 
The hypothesised mechanism underlying the observed differences may be due to the 
following explanations: i) HIV and/or ART exhibit changes in lactogenesis which alters 
breastmilk composition; or ii) breastmilk composition changes to accommodate the HIV-
exposed infant’s nutritional needs.  
Analyses according to gestation and ART period illustrated that length of ART exposure had 
non-significant effects on breastmilk composition. Sub-analyses indicated that the elevation 
in total energy and fat was more predominant in the breastmilk of late gestation HIV-
infected mothers with insufficient ART exposure. Fat significantly contributes to total energy 
and therefore the total energy is directly affected by the fat content. The physiological 
relevance of these findings remains unclear. However, proposed mechanisms supportive of 
the elevated breastmilk fat in women with insufficient ART exposure might be related to the 
normal rise in blood total cholesterol, low-density lipoprotein cholesterol (LDL) (Riddler 
2003) and high-density lipoprotein (HDL) cholesterol observed after ART initiation (Baker 
2011). It is hypothesized that these elevations in blood cholesterol affects the breastmilk 
composition of HIV-infected mothers during early treatment whereby increasing the total 
fat content of breastmilk.  
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Zinc is an essential micronutrient for optimal immune function (Dumrongwongsiri 2015), 
brain development and growth (Mathur 2015). Breastmilk zinc concentration was recently 
associated with low maternal zinc plasma levels (Dumrongwongsiri 2015). Low plasma zinc 
levels and inadequate zinc intake is prevalent in HIV–infected adults (Koch 1996; Carcamo 
2006, Baum 1997, Beach 1992, Jones 2006). Our results support this finding as low 
breastmilk zinc levels were found in the HIV-infected mothers and more so for those who 
received insufficient periods of ART treatment (<4 weeks) and who gave birth to lower 
gestational age infants.  Very low birth weight infants (VLBW), due to prematurity, are at 
particular risk for zinc deficiency which occurs mainly as a result of higher requirements 
combined with a low storage capacity (Jatinder 2004). The European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) currently recommends intake of at 
least 1.1-2.0 mg/kg/day for all VLBW infants (Agostoni 2010). Wulf et al. showed that zinc 
deficiency was associated with lower gestational age and with being small for gestational 
age (Wulf 2013). Our study supports this finding. The impact of these findings is of 
importance as zinc deficiency in HIV-infected patients contributes to a compromised 
antioxidant defence system which may have adverse effects for the mother and infant 
(Cunningham-Rundles 2005). Several studies had shown low zinc levels among LBW infants 
which correlates with increased morbidity and failure to thrive (Mathur 2015; Friel 1994; 
Halas 1983). Supplementation with 2mg/kg/day zinc gluconate enhanced neurological 
develeopmental outcomes, such as alertness and attention pattern, and decreased 
hyperexcitability, and proportion with abnormal reflexes. (Mathur 2015). 
Copper is required for the formation of enzymes, such as superoxide dismutase, which 
protects cells against oxidative damage, an outcome prevalent in prematurity. Neonates 
have low levels of ceruloplasmin, the transportation medium of copper, and its production 
only starts six to 12 weeks postnatally (Trindale 2005, Klein 2002, Agget 2000). The exact 
copper requirements for preterm infants are unknown; however, breastmilk provides 
adequate amounts (Trindale 2005, Reifen 1993). Interestingly, our results showed that HIV-
infected women had higher breastmilk copper levels and the significance was 
predominantly in late gestation women who received ART 4-20 weeks. Copper is an acute 
phase reactant and therefore studies showed that serum copper levels were in the higher 
reference values in HIV-infected adults, especially in the early phase of infection 
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(Stambullian 2007, Moreno 1998). Consequently, copper levels are a helpful marker to 
determine the progression to Acquired Immunodeficiency Syndrome (AIDS) (Stambullian 
2007, Moreno 1998). 
Conclusions 
In this study differences existed in the composition of premature breastmilk of HIV-infected 
and HIV-uninfected women. Significant deviations in breastmilk composition present with 
lower zinc and elevated fat in breastmilk of HIV-infected mothers after ART initiation which 
changes with progression of ART period. The variances in nutritive values in these milk 
samples do not, however, range outside the normal values of premature breastmilk 
composition. Further studies are warranted to confirm the differences and associated 
mechanisms in the composition of premature breastmilk of HIV-infected and HIV-uninfected 
women. 
Key messages 
Maternal HIV-infection and length of ART exposure exhibit changes in premature breastmilk 
composition. Breastmilk remains the first mode of enteral nutrition for premature HIV-
exposed infants.  
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Table 1: Maternal Demographic characteristics according to early and late gestation 
Characteristics Sample  
(n=74) 











Maternal Age (years), 
mean (SD)  
27.86 (5.57) 29.77 (6.2) 26.74 (5.0) 
 
0.10 





32.08 (0.71) 30 (2.80) 30.16 (2.06) 0.84 34.53 (1.46) 34.61 (1.29) 0.87 
Ethnicity    -------  1.00 
African 73 (99%) 22 (100%) 19 (100%) 
 
15 (100%) 17 (94%) 
 
Caucasian 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (6%) 
Educational level    0.18  0.63 
No formal education 14 (19%) 4 (18%) 6 (32%) 
 
3 (20%) 1 (6%) 
 
> Grade 10 20 (27%) 7 (39%) 1 (5%) 5 (33%) 7 (39%) 
≥ Grade 12 25 (34%) 7 (39%) 7 (37%) 4 (27%) 7 (39%) 
Tertiary education 15 (20%) 4 (18%) 5 (26%) 3 (20%) 3 (17%) 
HIV: Human Immunodeficiency Virus *Statistical significance p<0.05
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Mean (SD) or median (IQR) 
(n=74) 
HIV-infected on ART 
Mean (SD) or median (IQR) 
(n=38) 
HIV-uninfected 
Mean (SD) or median (IQR) 
(n=36) 
p-value* 
Total energy (kCal/100ml) 
(67-78kCal/100ml) 
68.23 (12.82) 69.82 (13.68) 66.54 (11.81) 0.27 
Protein (g/100g) 
(1.6-2.2g/100g) 
1.85 (1.67 to 2.15) 1.95 (1.73 to 2.28)  1.78 (1.59 to 1.98)  0.04* 
Carbohydrates (g/100g) 
(6.7-7.3g/100g) 
6.04 (1.98) 5.37 (1.75) 6.76 (1.21) 0.002** 
Fat (g/100g) 
(3.5-4.8/100g) 
3.97 (1.57) 4.42 (1.75) 3.49 (1.21) 0.01** 
PO4 (mg/l) 
(9.3-15.5mg/l) 
16.11 (14.9 to 19.1) 16.00  (14.93 to 18)  17.3 (14.51 to 22.7)  0.16 
Fe (mg/l) 
(0.9-3.7mg/l) 
2.58 (1.8 to 4.0) 2.36 (1.8 to 4)  2.76 (1.75 to 4)  0.72 
Zn (mg/l) 
(3.7-9.8mg/l) 
5.41 (4.39 to 6.37) 5.26 (4.12 to 6.10)  5.78 (4.73 to 6.81)  0.04* 
Cu (mg/l) 0.60 (0.16) 0.64 (0.15) 0.56 (0.15) 0.02* 
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HIV: Human Immunodeficiency Virus, ART: Anti-retroviral Therapy, IQR: Interquartile Range, PO4: Phosphate, Fe: Iron, Zn: Zinc, Cu: Copper, 
Significance defined as *p<0.05; **p<0.01 
 
ƗReference values adapted from (day 7-21 of lactation): Koletzko B 2014, Anderson DM 1983, Bishara 2008, Bauer J, Gerss J 2011, Kim 2012, 
Ronayne 2001, Tsang 2005.         
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Table 1: Nutritional composition of premature breastmilk from HIV-infected women according to ART period 
Breastmilk composition 
HIV-infected on ART <4 weeks 
Mean (SD) or median (IQR) 
(n=7) 
HIV-infected on ART 4-20 
weeks 
Mean (SD) or median (IQR) 
(n=13) 
HIV-infected ART>20 weeks 
Mean (SD) or median (IQR) 
(n=18) 
p-value* 
Total energy (kCal/100ml) 76.88 (10.61) 66.634 (15.42) 69.38(13.08) 0.28 
Protein (g/100g) 2.08 (0.37) 2.11 (0.47) 1.91 (0.31) 0.32 
Carbohydrates (g/100g) 4.85 (2.40) 5.35 (1.22) 5.58 (2.15) 0.70 
Fat (g/100g) 3.49 (1.21) 5.40 (1.65) 4.32 (1.87) 0.24 
PO4 (mg/l) 13.55 (11.6 to 15.5) 18.67 (12.19 to 19.25) 16.78 (15.2 to 18.95) 0.19 
Fe (mg/l) 2.74 (1.52) 3.15 (1.70) 3.28 (2.33) 0.75 
Zn (mg/l) 4.86 (1.86) 5.17 (2.57) 5.22 (1.31) 0.91 
Cu (mg/l) 0.57 (0.15) 0.69 (0.15) 0.62 (0.15) 0.99 
* Significance p<0.05. HIV: Human Immunodeficiency Virus, ART: Anti-retroviral Therapy, IQR: Interquartile Range PO4: Phosphate, Fe: Iron, Zn: 
Zinc, Cu: Copper  
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Table 2: Breastmilk composition of mothers who gave birth to premature infants 24-33 weeks gestation according to HIV status and ART 
*Significance defined as p<0.05. HIV: Human Immunodeficiency Virus, ART: Anti-retroviral Therapy, IQR: Interquartile Range PO4: Phosphate, 
Fe: Iron, Zn: Zinc, Cu: Copper 
  
Breastmilk composition 
Gestation: 24-33 weeks 
HIV-infected (n=23) 
HIV-uninfected 
Mean (SD) or median (IQR) 
(n=24) 
p-value* 
ART <4 weeks 
Mean (SD) 
Mean (SD) or median 
(IQR) (n=4) 
ART 4-20 weeks 
Mean (SD) or median 
(IQR) (n=8) 
ART >20 weeks 
Mean (SD) or median 
(IQR) (n=11) 
Total energy (kCal/100ml) 75.86   (10.27) 61.85    (16.86) 68.68 (14.08) 70.16    (12.22) 0.34 
Protein (g/100g) 2.01 (0.22) 2.25 (0.53) 1.93 (0.39) 1.99 (0.42) 0.28 
Carbohydrates (g/100g) 4.66 (2.97) 5.85 (1.16) 5.04 (1.22) 6.76 (1.26) 0.12 
Fat (g/100g) 5.4 (1.41) 3.57 (1.63) 4.21 (1.69) 3.84  (1.18) 0.18 
PO4 (mg/l) 13.56 (11.60 to 15.52) 18.67 (12.19 to 19.25 16.79 (15.20 to 18.95) 20.68 (17.2 to 23.5) 0.17 
Fe (mg/l) 2.55 (1.56 to 3.54) 3.27 (1.83 to 4.43) 2.28 (1.61 to 2.98) 3.95 (2.4-5.1) 0.11 
Zn (mg/l) 4.03 (3.07 to 4.99) 5.15 (2.21 to 6.68) 5.44 (4.57 to 6.11) 6.83 (5.4 to 7.45) 0.03* 
Cu (mg/l) 0.58 (0.12) 0.63 (0.12) 0.63 (0.19) 0.58 (0.16) 0.78 
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Table 3: Breastmilk composition of mothers who gave birth to premature infants 34-37 weeks gestation according to HIV status and ART 
* Significance defined as p<0.05. HIV: Human Immunodeficiency Virus, ART: Anti-retroviral Therapy, IQR: Interquartile Range PO4: Phosphate, 
Fe: Iron, Zn: Zinc, Cu: Copper
Breastmilk Composiion 




Mean (SD) or median 
(IQR) (n=15) 
ART <4 weeks 
Mean (SD)  or median 
(IQR)  (n=3) 
ART 4-20 weeks  
Mean (SD) or median 
(IQR)  (n=5) 
ART >20 weeks  




78.22 (13.23) 74.30 (9.84) 70.46 (9.84) 61.48 (9.39) 0.03* 
Protein (g/100g) 2.16 (0.56) 1.99 (0.28) 1.88 (0.28) 1.71 (0.44) 0.07 
Carbohydrates (g/100g) 5.11 (1.96) 5.85 (1.16) 5.52 (2.14) 6.76(1.26) 0.20 
Fat (g/100g) 5.39 (2.29) 4.75 (1.20) 4.48 (2.25) 3.00 (1.10) 0.04* 
PO4 (mg/l) 15.27 (2.61) 17.55 (1.67) 15.66 (3.65) 14.88 (3.80) 0.52 
Fe (mg/l) 3.00 (1.40-4.60) 2.96 (1.96 to 3.66) 4.86 (2.2 to 6.48) 2.44 (1.5 to 2.69) 0.20 
Zn (mg/l) 5.97 (3.61 to 8.1) 5.21 (4.38 to 5.49) 4.87 (3.96 to 6.02) 5.28 (4.32 to 6.49) 0.76 
Cu (mg/l) 0.56 (0.21) 0.80 (0.15) 0.61    (0.07) 0.52 (0.14) 0.05 
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ARTICLE 2:  
 
Anthropometric Parameters of HIV-infected and HIV-uninfected Mothers and their 
Premature Infants. 
  





Pregnancy outcomes, such as premature birth and intra-uterine growth restriction (IUGR) 
are associated with human immunodeficiency virus (HIV)-infection during pregnancy. 
Women with chronic undernutrition and obesity are more likely to give birth to IUGR 
premature infants. The objectives of the study were, to assess the maternal anthropometric 
parameters of HIV-infected and HIV-uninfected mothers. Furthermore this study aimed to 
determine the effects of anthropometric parameters, HIV status and the ART exposure on 
the anthropometric parameters of premature infants. 
Participants and Methods 
Study participants included HIV-infected and HIV–uninfected mothers who gave birth to 
premature infants. Maternal anthropometric data [weight, height and mid-upper arm 
circumference (MUAC)] were collected on day seven postpartum. Infant anthropometric 
data [weight, length and head circumference (HC)] were obtained at birth and length and 
HC were repeated on day seven postpartum. Demographic information was obtained 
through a questionnaire. Clinical information was obtained from the hospital files. 
Results 
The study population consisted of 74 mother-infant-pairs. This grouping comprised of 38 
(51%) HIV-infected and 36 (49%) HIV-uninfected mothers and their premature infants.  All 
HIV-infected mothers received ART. The mean maternal body mass index (BMI) was 
26.7kg/m2 (SD±4.88) and MUAC was found to be within normal ranges (mean 28.9cm; 
SD±3.93). Maternal underweight (n=7; 9%) and obesity prevalence was low (n=7; 9%). There 
was a high prevalence of IUGR (n=40; 54%). Neither maternal anthropometric parameters 
(p=0.79) nor HIV-status and ART regime (p=0.72) was associated with IUGR. Similarly, the 
nature of IUGR (symmetrical vs. asymmetrical) was not associated with maternal HIV-status 
(p=1.00). Head circumference restriction was lower in women with sufficient ART exposure 
periods (p=0.003).  
 
 




Maternal anthropometric parameters, -HIV status and –ART exposure had no effect on the 
incidence of IUGR. Sufficient maternal ART exposure may positively influence head 
circumference at birth. 
  




A premature infant is defined as an infant born <37 weeks’ gestation.1 Fifteen million 
premature births occur worldwide of which 60% of these deliveries occur in low-and middle 
income countries.2  Premature delivery is considered  a significant global perinatal health 
problem with a rising incidence in Southern Africa.3 In a meta-analysis by Beck and 
colleagues, the worldwide prevalence of premature birth was 9.6% and 85% of these 
preterm births were from the African and Asian continent.3 Evidence from developing 
countries suggest that human immunodeficiency virus (HIV)-infected mothers have an 
increased risk of giving birth to premature infants and the occurrence is directly associated 
with clinical stage of disease.4-6  Research show that HIV-infected women were more likely 
to give birth to low birth weight (LBW) and intra-uterine growth restricted (IUGR) premature 
infants.2,5,6  The role of anti-retroviral therapy (ART) in IUGR is uncertain. Studies conducted 
in the developed world showed no association between in utero exposure to ART and 
IUGR,5, 7-9 however results obtained from the developing world are conflicting.9-12  
Maternal anthropometric parameters during pregnancy are key factors in determining 
foetal growth and anthropometrical parameters at birth. In South Africa, poor household 
food security and the effects of HIV/AIDS Wasting Syndrome, or the combination thereof, 
may contribute to maternal undernutrition.13 In the undernourished mother, the supply of 
maternal- foetal nutrients are compromised, thereby restricting foetal growth. Foetal 
growth is more affected by chronic maternal undernutrition than nutrient restriction during 
the pregnancy period.14 
In addition to undernutrition, the incidence of overweight and obesity is rising dramatically 
in South Africa.11 In a small subset of people, maternal overnutrition may increase the risk of 
delivering a premature IUGR infant, though the exact mechanisms are poorly understood.15 
An observational study found that obese women had a higher rate of IUGR deliveries as well 
as an increased frequency of admissions to the neonatal intensive care unit.16 Maternal 
overnutrition impedes placental growth and ultimately leads to growth faltering which 
significantly increases neonatal morbidity and mortality.17 Highly active antiretroviral 
therapy (HAART) use is often associated with overnutrition, metabolic- and endocrine 
abnormalities.18 
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The objectives of this study were to assess the maternal anthropometric parameters of HIV-
infected and HIV-uninfected mothers as well as to assess of the neonatal anthropometric 
parameters of premature infants in relation to maternal anthropometric parameters 
(weight, height and MUAC), HIV status and ART regimen. 
Methodology 
A cross-sectional study with an analytical component was conducted in the postnatal wards 
of Kalafong Hospital, Gauteng, South Africa from August 2014 to April 2015.  
Consecutive sampling was used to recruit participants. The study population included 
postnatal lactating HIV-infected mothers receiving ART and HIV-uninfected mothers who 
gave birth to premature infants. All mothers received accommodation in the ward as per 
standard protocol. The sample size was estimated by a statistician based on data of live 
births from the institution.  
Consecutive consenting postnatal mother-premature infant pairs were included in the 
study. The study population consisted of HIV-infected and HIV-uninfected mothers who 
gave birth to premature infants. All HIV-infected mothers received ART. An HIV positive 
status was established by a routine confirmed positive rapid HIV test during the prenatal 
period and an HIV negative status was confirmed with a routine ELISA test in the postnatal 
period. Gestational age was estimated by using the Ballard score as early sonars are rarely 
performed. Standard means of medical treatment was continued during the study period. 
A researcher-administered questionnaire, tested for face and content validity during a pilot 
project, was used in order to obtain demographic and clinical information from the mother. 
Information regarding HIV status, ART regimen and CD4 count was collected. Maternal 
anthropometric information was obtained on day seven postnatally. This included: weight, 
height and the mid-upper-arm-circumference (MUAC). Maternal undernutrition was 
classified as a BMI <20.318 and/or MUAC <214mm19 and maternal overnutrition was defined 
as a BMI >25kg/m2.20 Birth infantile anthropometric information was obtained from the 
patient folder. This included birth weight, -length and head circumference (HC). A trained 
dietitian repeated the length and HC measurements on day seven postnatally according to 
standardised procedures.20 IUGR was defined as a weight, length or head circumference 
<10th percentile.1 Symmetrical IUGR (s-IUGR) is defined as a weight, length and HC <10th 
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percentile and a ponderal index (PI) ≥2.0 and asymmetrical IUGR (a-IUGR) as weight <10th 
percentile with the sparing of length and HC and a PI <2.0.22,23 Medical information were 
noted from the hospital file. 
Data captured on Microsoft Excel 2013® was exported to Statistica version 12 (StatSoft Inc. 
[2015] STATISTICA [data analysis software system], www.statsoft.com) for data analysis. 
Statistical analysis was done with the assistance of Tygerberg Biostatistics Unit, Stellenbosch 
University. Descriptive statistics were used to report the demographics of participants. 
When groups were compared, ANOVA and t-tests were used. Statistical significance was 
defined as p<0.05. 
The study was granted ethics approval from the Human Research Ethics Committee of 
Stellenbosch University (S13/09/165) and the Research Ethics Committee of the Faculty of 
Health Sciences at the University of Pretoria (191/2014). The study was conducted in 
accordance with Good Clinical Practice Guidelines. 
Results 
A total of 92 mother-infant pairs were screened for inclusion in the investigation. Seventeen 
pairs were excluded of which twelve mothers were discharged before data collection 
procedures were completed, two mothers did not have adequate breastmilk volumes to 
provide a second sample, one mother were not on ART at the time of data collection and 
two mothers were excluded due to an ELISA test not performed. One mother declined 
consent.  The final sample consisted out of 74 mother-infant pairs. Thirty eight (51%) 
mothers were HIV-infected and 36 (49%) were HIV-uninfected. All HIV-infected mothers 
received a fixed dose combination (FDC) ART which consist of tenofivir, emtricitabine and 
efavirenz.24 The mean ART treatment period was 8.9 months (SD±15.4; 1 day-7 years). In 
this group, the mean CD4 was 367cells/mm
3 (SD±165; CI=51-720) cells/mm3. There were no 
significant differences in the demographic characteristics of mothers or infants. The mean 
gestational age of HIV-exposed infants were 31.8 weeks (SD±3.2) and of HIV-unexposed 
were 32.4 weeks (SD±2.86). The mean birthweight was 1468g (SD±458.8g), length 40.7cm 
(SD±5.0cm) and HC 28.7cm (SD±3.1cm).  The demographic characteristics are depicted in 
Table 1. 
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The mean maternal BMI was 26.7kg/m2 (SD±4.88 kg/m2, CI=25.7-27.9), and the mean MUAC 
was 289mm (SD±3.93mm; CI=28.0-29.8). Under- and overnutrition prevalence was low with 
7 (9%) mothers classified as underweight and 7 (9%) as overnourished. Most mothers’ 
(n=59; 80%) anthropometric parameters fell within normal ranges. The mean BMI and 
MUAC did not differ between HIV-infected and -uninfected mothers (p=0.89 and p=0.71 
respectively). Furthermore ART exposure duration had no significant effect on maternal 
anthropometrical parameters (Figure 1). 
IUGR was present in 40 (54%) of the premature infants. Of these, 13 (33%) were s-IUGR 
(PI≥2.0) and 27 (67%) were a-IUGR (PI<2.0) indicating wasting at birth. Similar incidence of 
IUGR was found in infants born to HIV-infected and HIV–uninfected mothers. Furthermore, 
no significant differences (p=1.00) existed between infants with s-IUGR and a-IUGR 
according to maternal HIV status. Maternal anthropometric classifications (p=0.79) and 
maternal HIV-infection and -ART regimen (p=0.82) had no effect on the prevalence of IUGR 
(Table 2). No differences existed for birthweight (p=0.18) and length (p=0.15) or HC (p=0.27) 
between infants born to HIV-infected and HIV–uninfected mothers. HIV exposure did not 
influence birthweight (p=0.18), length (p=0.15) or HC (p=0.27). Maternal ART exposure time 
had no effect on infantile weights and lengths (p=0.764 and p=0.647 respectively), however 
infants of mothers who received ART for >20 weeks showed significantly less restrictions 
related to their head circumference measurements (p=0.003). Maternal ART exposure had 
no effect on birthweight categories (Figure 3). Similarly, maternal CD4 cell counts had no 
effect on the incidence of IUGR. 
  












Ethnicity   p=0.3 
African 38 (100%) 35 (97%) 
 
Caucasian 0 (0%) 1 (3%) 
Age in years  
mean (SD) 
29 (5.57) 27 (5.11) p=0.18 
Education Level (%)  p=0.76 
No formal education 7 (19%) 7 (18%) 
 
> Grade10 12 (33%) 8 (21%) 
≥ Grade 12 11 (31%) 14 (3%7) 
Tertiary level 8 (22%) 7 (18%) 
*Significance defined as p=0.05 
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Figure 1: Maternal anthropometric data, -HIV status and ART exposure period. Maternal 
BMI (A) and MUAC (B). HIV: Human immunodeficiency virus, ART: Antiretroviral Therapy, 
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Table 2: Neonatal anthropometric parameters according to maternal HIV status, -








n (%) n (%) 
HIV Status  p=0.72 
HIV-infected on ART 20 (50%) 18 (53%) 
 
     ART <4 weeks  5 (25%) 2 (11%) 
     ART 4-20 weeks  7 (35%) 6 (33%) 
     ART >20 weeks  8 (40%) 10 (56%) 
HIV-uninfected  20 (50%) 16 (47%) 
Maternal  Status  p=0.79 
Undernourished  3 (8%) 4 (12%) 
 Normal  33 (82%) 27 (79%) 
Overnourished  4 (10%) 3 (9%) 
HIV: Human Immunodeficiency Virus, ART: Antiretroviral Therapy, IUGR: Intra-uterine 
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Figure 2: Anthropometric parameters <10 percentile of HIV-exposed premature infants 




Figure 3: Birtweight according to maternal ART exposure time and HIV-uninefected 
mothers. ART: Antiretroviral Therapy, LBW: Low Birth Weight, VLBW: Very Low Birth 
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Early recognision of HIV infection is a key strategy in decreasing mother to child 
transmission. It is evident that the current PMTCT programme is effective when comparing 
the mean ART treatment period and mean gestation periods.  
Our results did not show an association between maternal HIV-infection and adverse 
pregnancy outcomes, such as premature birth and IUGR. This is conflicting to numerous 
studies from Sub-Saharan Africa that reported significant results.4-6 The short- and long-term 
effects of ART on in utero development are unknown, particularly in developing countries. 
While some studies found that maternal antiretovial drugs compromised neonatal 
anthropometric classification,5,7-9 others, including ours, did not.9-12  Anthropometrics 
(birthweight, length and HC) and birthweight categories were not influenced by maternal 
HIV-status or –ART use. While ART may increase the risk for LBW, 5,7-9  the importance of 
maternal ART provision is imperative to prevent MTCT of HIV. However, other strategies to 
prevent LBW should be optimised as LBW infants are at higher risk of mortality compared to 
a term appropriate for gestation infant.25 
Mothers had a mean BMI of 27.6kg/m2 which suggests a risk for overweight among 
childbearing women. The prevalence of IUGR was high (53%) in this group. The combination 
of mothers at risk of overweight and infants being born with IUGR have important 
implications for HIV-infected and HIV-uninfected women of reproductive age as it indicates 
possible metabolic disturbances for them and their offspring. The role of ART may further 
disturb clinical anthropometric and metabolic parameters. ART is associated with metabolic 
aberrations, including central obesity, dyslipidaemia and insulin resistance.18 Although 
maternal anthropometrics were not influenced by ART exposure time, the possibility of pre-
pregnancy- or future morphological and/or metabolic effects should not be excluded. 
Epidemiological studies and animal models associate LBW with risk of adult obesity and 
metabolic syndrome.  Maternal overnutrition, whether from obesity, high fat diets or 
excessive weight gain in pregnancy, has delivered varied results concerning birth weight. 
However, in the adult offspring, obesity and metabolic abnormalities are highly prevalent 
indicating evidence of metabolic programming.26-29 The intrauterine exposure to endocrine 
disrupting chemicals (or obesogens), present in overweight mothers, alter the 
developmental programming of adipogenesis of the foetus through gene expression. The 
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developing foetus responds by producing structural and functional changes in tissues and 
organ systems, known as foetal programming, which result in increased plasticity of 
adipocytes.30 
A third (32%) of infants with IUGR presented with low HC measurements. Subanalyses 
demonstrated a higher incidence of HC restriction among women with ART exposure <20 
weeks and insufficient ART exposure. This holds important implications as an impaired HC at 
birth is a strong indicator of impaired neurodevelopmental outcomes in childhood.31 Studies 
that explored prenatal exposure to ART did not find differences in infant 
neurodevelopmental outcomes.32,33 The results indicate the possibility that increased ART 
exposure might protect infants against impaired brain development, as seen in studies on 
longer  ART duration and association with reduction of some neurologic impairment in 
children.34 
Conclusion 
Maternal anthropometric parameters, -HIV status and –ART exposure showed no 
association with IUGR in this study. Sufficient maternal ART exposure may positively 
influence head circumference at birth. 
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CONCLUSIONS AND RECOMMENDATIONS 
4.1  Summary of Study Objectives and Design 
Premature delivery is considered  a significant global perinatal health problem with rising 
incidence in Southern Africa.1 HIV-infected women receiving ART are more likely to give 
birth to premature- and IUGR infants.2  The current South African HIV infant feeding 
guidelines promote exclusive breastfeeding with dual provision of ART to HIV-infected 
mothers and HIV-exposed infants.4,5 The breastmilk composition of mothers of premature 
infants is highly variable and is influenced by factors that include stage of lactation,6-10 
duration of lactation,11-13 length of gestation,14,15 maternal anthropometric parameters16 
and HIV-infection.17  Extensive literature exists to show that ART has various effects on 
metabolic and endocrine systems;18 however, the effect of ART on breastmilk composition is 
largely unknown. Recent research found differences in breastmilk composition between 
HIV-infected and HIV–uninfected women with term infants.17 
The primary aim of the investigation was to assess and compare the breastmilk composition 
of HIV-infected mothers receiving ART and HIV-uninfected mothers who had given birth to 
premature infants. The objectives were as follows: 
i. To describe the HIV-infected mother population with reference to the use of ARV 
treatment schedule and disease state. 
ii. To compare the breastmilk components of HIV-infected mothers receiving ART, 
according to the ART regimen, in other words HAART and PMTCT, with those of HIV-
uninfected mothers. 
iii. To assess the maternal anthropometric parameters (weight, height and MUAC) of 
HIV-infected and HIV-uninfected mothers. 
iv. To assess the neonatal anthropometric parameters of premature infants in relation 
to maternal anthropometric parameters (weight, height and MUAC), HIV status and 
ART regimen. 
A cross-sectional study with an analytical component was conducted in the postnatal units 
of Kalafong Hospital, Pretoria; South Africa from August 2014 till April 2015. Mothers were 
included if: 1) they had given birth to a premature infant (24-37 weeks gestation); 2) were 
breastfeeding exclusively; and 3) if HIV-infected mothers received ART. Inclusion cirteria of 
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infants were: 1) ≥24-37 weeks gestational age (24-33 weeks were classified as earlier 
gestation and 34-37 weeks as later gestation); 2) were breastfed exclusively- either mother’s 
own milk or donor breastmilk; 3) HIV-unexposed or HIV-exposed on prophylaxic ART, 4) first 
born infant of twins.   
The study population was divided into four subgroups for comparison:  
i.  HIV-uninfected lactating women receiving ART who gave birth to premature infants 
34-37 weeks gestation; 
ii. HIV-uninfected lactating women receiving ART who gave birth to premature infants 
24-33 weeks gestation; 
iii. HIV-infected lactating women who gave birth to premature infants 34-37 weeks 
gestation; 
iv. HIV-infected lactating women who gave birth to premature infants 24-33 weeks 
gestation. 
v. First born infant of twins 
The data of HIV-infected mothers were analysed according to length of ART exposure. ART 
exposure was seen as short treatment duration when ART was initiated <4 weeks before 
birth. Furhermore there was distinguished between ART treatment use 4-20 weeks and >20 
weeks. 
All mothers were encouraged to initiate breastfeeding or to express breastmilk within one 
day of giving birth.  Breastmilk samples were collected on day seven and nine of lactation 
for macronutrient and micronutrient analyses respectively. Each mother provided two 
samples of 30ml breastmilk that had been expressed manually. A researcher-administered 
demographic questionnaire was completed, and medical/clinical information was obtained 
from the hospital file (refer to Addendum A). Maternal anthropometric measurement were 
performed on day seven postpartum. Infantile birth anthropometric information was 
obtained from the hospital file. The length and head circumefence were measured on day 
seven of life. Gestation was classified by using the Ballard score in the absence of an early 
sonar. Normal standard of care was practised during the course of the study. 
Breastmilk samples were analysed for total solids, ash, protein, lactose, fat, phosphorus, 
iron, zinc and copper. Total carbohydrates and total energy were calculated. All breastmilk 
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samples were raw, untreated samples, and therefore had not undergone any pasteurisation 
procedures. 
The total study population consisted of 74 consenting mother-infant pairs. Thirty eight pairs 
(51%) were HIV-infected/ HIV-exposed and 36 (49%) pairs were HIV-uninfected/ HIV-
unexposed. 
4.2  Addressing the study objectives 
In this section, each objective will be described and interpreted within the context of the  
results of the research. 
4.2.1 Description of the HIV-infected mother population and ART use 
ART is an effective way of reducing the viral load, increasing the maternal CD4 count
19
 and 
minimizing the postnatal risk of MTCT of HIV through breastmilk.20 When ART is available, 
MTCT of HIV can be reduced by 1–2%.21 The 2015 Consolidated National Guidelines for 
PMTCT and management of HIV in children, adolescents and adults recommend that all HIV-
infected pregnant and lactating mothers receive ART for the duration of pregnancy and 
lactation. HIV-infected women are eligible for initiation of ART irrespective of CD4 count.
22 As 
of 2012, all HIV-infected pregnant women are initiated on FDC ART, which is a single-pill 
combination of tenovovir, emtricitabine and efavirenz.22  
In a recent retrospective descriptive study conducted at Kalafong Hospital, the cumalitive 
incidence of HIV-infection at four weeks of life was found to be 25 out of every 1000 (2.5%) 
live births among VLBWh infants. It is standard practice to provide infants with a single dose 
of nevirapine and raw breastmilk from the mother while providing mothers with ART.23 The 
incidence of HIV-infection among these infants was comparable to statistics from Groote 
Schuur Hospital (incidence of 27 out of every 1000 at four weeks of life) where it is protocol 
to pasteurise breastmilk in addition to providing ART.24 This data proves that raw breastmilk 
in conjuction with dual ART for mother and infant is a safe feeding option for premature 
infants. 
It was not within the scope of this study to determine the prevalence of HIV-infection; 
however, a study conducted in the neonatal wards of Kalafong Hospital in 2005 indicated 
                                                          
h
 VLBW infants are defined as infants born with a birthweight <1500g 
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that the prevalence of maternal HIV-infection was 26.3%,25 and national data showed that 
30% of women attending antenatal clinics were HIV-infected in 2008.26  
The results of this investigation indicated that all HIV-infected mothers received FDC ART. 
The CD4 count of HIV-infected mothers varied widely (CI=51-720 cells/mm
3) with mean CD4 
count of 367cells/mm3 (normal CD4 range between 500- and 1500 cells/mm
3).27 Seven (10%) 
mothers had received ART for <4weeks. It is practice in Kalafong Hosptital to provide infants 
whose mothers received <4 weeks ART with donor breastmilk for the first 3- 4 weeks of life. 
In light of this practice, the researchers viewed this period as insufficient time to prevent 
MTCT of HIV. The period of ART exposure elicited fascinating results with regard to 
breastmilk composition. It did not affect maternal anthropometrics, but sufficient ART 
exposure showed a positive effect on HC in the infants. Details regarding breastmilk 
composition and anthropometics will be discussed in section 4.2.2 and 4.2.3 respectively. 
4.2.2  Breastmilk Composition of HIV-infected Women receiving ART 
HO: There is no difference between the breast milk composition of HIV-infected mothers 
receiving ART and HIV-uninfected mothers who gave birth to a premature infant.  
There is a high incidence of premature birth among HIV-infected women which associates 
directly with disease staging.2,28,29 A recent African study showed that 19.1% of premature 
births are from HIV-infected women.30  With the advancement of ART regimes, an increase 
in prematurity has been observed in developing countries.31-34 It is well known that ART 
exerts potent metabolic- and endocrine side-effects such as dyslipidaemia, glucose 
intolerance and bone mineral abnormalities18 with several metabolic aberrations occurring 
soon after ART initiation.35,36 However, the effects of HIV-infection and ART on breastmilk 
composition is unknown. The literature is deficient in studies that investigated the 
compositional differences in breastmilk between HIV-infected and –uninfected women. 
Recently, De Wet et al demonstrated differences between HIV-infected and HIV-uninfected 
women from Mangaung who had given birth to term infants.17 
The results of this study indicated significant differences between HIV-infected women 
receiving ART and HIV-uninfected women who had given birth to premature infants. 
Protein, fat and copper levels were higher while carbohydrates and zinc were lower in HIV-
infected women compared to HIV-uninfected women. Differences were more prominent 
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when groups were divided according to HIV status alone, than when groups were divided 
according to HIV status and gestation duration. Interestingly, all compositional factors were 
not consistently higher or lower in HIV-infected women receiving ART, in other words, some 
nutrients were higher and others were lower when compared to HIV-unifected women’s 
breastmilk.  
The results demonstrated that breastmilk samples with a higher fat content was 
predominantly from late gestation HIV-infected women with ART exposure <4 weeks. Very 
few studies have investigated the metabolic and/or nutritional effects soon after ART 
initiation. Studies have shown that there is a rapid increase in total cholesterol, HDL 
cholesterol and LDL cholesterol.35,36 Considering the results of the investigation, it seems as 
if there is a dramatic metabolic deviance soon after ART initiation that possibly also 
influences breastmilk composition. 
The significance of the lower zinc levels observed among HIV-infected women was 
predominantly from early gestation period women with <4 weeks ART exposure. Zinc is of 
great importance in growth, and brain development.38 The impact of these findings are 
important since zinc deficiency in HIV-infected patients contribute to a compromised 
antioxidant defence system which may have adverse effects for the mother and infant.39  
Copper acts as an essential cofactor in many enzymes involved in metabolic reactions, such 
as angiogenesis, oxygen transport and antioxygen defences.40,41 Pregnancy induces a sudden 
rise in plasma copper levels which return to pre-pregnancy values shortly after delivery, 
partly as a result of ceruloplasmin synthesis. Ceruloplasmin is a copper-binding protein 
which is influenced by oestrogen42 and is a major acute phase reactant.43 Differences in 
copper levels were found among late gestational women with ART exposure of 4-20 weeks, 
possibly indicating higher stress levels among this group. HIV-infection is associated with 
increased inflammation levels, opportunistic infections, AIDS-associated malignancies and 
several non-infectious conditions. These condititions often become visible shortly after the 
initiation of ART.44 
There is a deficit in studies conducted on the breastmilk concentration of HIV-infected 
women with preterm infants. It is however important to keep in mind that serum levels of 
HIV-infected women cannot be extrapolated to breastmilk concentrations. Although 
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differences were found, the variances in nutritive values in these milk samples did not, 
however, range outside the normal values of premature breastmilk composition. Further 
studies are warranted to confirm the differences and associated mechanisms. 
The results demonstrated intruiging results on the contribution of ART exposure in 
breastmilk composition, however the contributrion of disease stage (or degree of 
immunosuppression) remain to be explored. 
Interestingly, a linear incline or decline was observed for all nutrients with ART exposure 
period. Although differences existed, the composition values still fell into the upper-or lower 
range observed in other studies.45-51 It is well-known that preterm breastmilk does not fully 
meet the nutritional requirements of premature infants and needs to be fortified.51  
Literature shows that breastmilk is not influenced by maternal nutritional status, except in 
severe starvation conditions.53 The researchers did not account for this in the results due to 
the following reasons:  
i. Only anthropometric and clinical data were collected. In order to obtain a complete 
picture of nutritional status, biochemical, clinicaland dietary information are also 
needed. 
ii. The number of mothers that were classified as under- and overnourished were low 
[n=7 (9%) and n=7 (9%) respectively]. 
The the null hypothesis is rejected. A destinct difference was found in the nutritive breastmilk 
composition of HIV-infected mothers receiving ART and that of HIV-uninfected mothers who 
gave birth to a premature infant, bearing in mind that the values were within the normal 
range of recorded premature breastmilk composition.  
4.2.3  Maternal Anthropometric parameters of HIV-infected women 
HO: Maternal anthropometric parameters, HIV status and ART regime do not affect neonatal 
anthropometric parameters at birth 
Although HIV-infection is not associated with adverse birth outcomes in first world 
countries,2,53 several African studies have shown an increased incidence of prematurity, LBW 
and IUGR among HIV-infected women.2,28 It is difficult to demonstrate the relative 
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contribution of HIV to these parametres due to small samples and a lack of HIV-specific data 
from the available studies. Moreover, studies included different subtypes of HIV. In South 
Africa, the clade C subtypei is most predominant which is associated with increased MTCT of 
HIV and progression to AIDS.2 Progression of HIV disease increases the risk of delivering 
IUGR infants.2,28,53-55 The role of HAART in IUGR is uncertain. Studies conducted in the 
developed world showed no association between in utero exposure to HAART and IUGR,28,29 
but results obtained from the developing world are conflicting.49-55 Recently, efavirenz-
based ART regimens were shown to correlate with an increase in adverse birth outcomes, 
including birth defects, stillbirths, abortion, LBW and prematurity.56  
Chronic undernutrition, often resulting from HIV infection, leads to foetal growth restriction 
and SGA infants.57 On the other side of the malnutrition coin, the incidence of overweight 
and obesity is rising dramatically in South Africa.58  In a small subset of people, maternal 
overnutrition may increase the risk of delivering a premature IUGR infant, though the exact 
mechanisms are poorly understood.59 Obesity is often associated with chronic diseases of 
which the effects on birth outcomes are unquantified.60 Furthermore, many research studies 
are investigating the effects of metabolic programming on the offspring of overweight and 
obese women. Exposure to endocrine disrupting chemicals causes adverse genetic changes 
that passed on from mother to fetus, which in turn predisposes the infant to obesity and 
chronic diseases later in life.61  
The results of this study indicated a high prevalence of IUGR (53%) in the study population. 
Gilfillan and colleagues explored the characteristics of African women who had given birth 
to premature IUGR infants at Kalafong Hospital. The results indicated that maternal age, 
nutritional status, birth spacing, smoking and alcohol use during pregnancy as well as 
hypertension during the last trimester contributed to IUGR birth.25 The PI, defined as weight 
(g) / length (cm)3, is a simple and valuable method to identify wasting or disproportionate 
IUGR at birth. A PI of <2.0 is defined as low in premature infants. A large proportion (67%) of 
infants had a low PI. Poor weight gain with the preservation of length and/or severe 
nutritional insults in the third trimester leads to a low PI. On the other hand, a third of 
infants presented with s-IUGR. Chronic maternal undernutrition and the presence of 
                                                          
i
 Clade C subtype: The strain of HIV-1 into four groups, namely groups M, N, O and P. In the M-group several 
subtypes/clades of HIV can be distinguished. Subtype/clade C is predominantly found in Southern Africa and is 
associated with an increased disease progression compared to clade A. 
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untrauterine infections are associated with s-IUGR. The high incidence of IUGR in this 
population has serious future health consequences. No prospective studies had been 
conducted in our population, but data links IUGR with chronic diseases (coronary heart 
disease, Type II Diabetes Mellitus, hypertension and stroke) in adulthood.62 
The results of this investigation indicated that maternal HIV-status and CD4 count were not 
associated with IUGR; therefore, other maternal factors (including the factors mentioned 
above) could have contributed to this occurrence. Furthermore, there was no association 
between maternal anthropometric parameters and IUGR in its entirety. This might be due to 
the relatively low prevalene of underweight (9%) and overnourished mothers (9%) in the 
sample.  In addition, the type of IUGR was not affected by the maternal HIV status and ART 
regimen. A significant association existed between maternal duration of ART treatment and 
head circumference restriction at birth. A higher incidence of head circumference restriction 
was found among women with ART exposure <20 weeks. This holds important implications 
as an impaired head circumference at birth is a strong indicator of impaired 
neurodevelopmental outcomes in childhood.63 Studies that explored prenatal exposure to 
ART did not find differences in infant neurodevelopmental outcomes.64,65 The results 
indicated the possibility that increased ART exposure protects against impaired brain 
development. This finding corresponds with studies which found that a longer ART duration 
was associated with reduction of some neurologic impairment in children.66 
The null hypothesis that states “maternal anthropometric parameters, HIV status and ART 
regime do not affect neonatal anthropometric parameters at birth” is therefore partially 
accepted.  
4.3 LIMITATIONS OF THE INVESTIGATION 
The following limitations may have influenced the results of the investigation: 
i. The initial goal was to include 25 mother-infant pairs in each of the four 
subgroups in order to obtain an effect size (RMSEE) of 0.45. However, due to 
slow enrolment of the HIV-infected groups, only 17 mother-infant pairs were 
included in each of the four subgroups, giving an effect size (RMSEE) of 0.55. The 
proportionate prevalence of HIV-exposed versus HIV-unexposed infants led to 
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lower patient numbers and a strenuous data collection period with financial 
constraints.  
ii. When it was not possible to take the infant’s length on a length board (e.g. 
intubated infants), a non-strechable measuring tape was used which is not as 
accurate as a length board. 
iii. Although corrected for, some mothers presented with oedema which may have 
influenced precision of the anthropometrical measurements. BMI was however, 
adjusted to correct for oedema. 
iv. A high number of non-South African patients are admitted to Kalafong Hospital. 
This might have led to variablility in the study population. 
v. Mothers who gave birth to twins were included in the study (n=9). The first born 
twin was included. Breastmilk values may be different to mothers who deliver to 
singleton infants. Twins frequently have a shorter gestation period and lower 
birth antropometrics.  
vi. Low percentages of underweight and obese mothers were present in the study 
population. Therefore, it was difficult to show significant associations regarding 
their anthropometrics and IUGR of their infants. 
The following data could have strengthened the results of the study: 
i. Blood tests: total protein, albumin, pre-albumin and C-reactive protein, urea and 
creatinine: useful measurements to determine nutritional status and levels of stress 
(acute phase response). 
ii. Dietary intake (e.g. food frequency questionnaires, 24-h recall, and 3-day diet 
history): To strengthen nutritional status classifications and determine effect on 
certain limited parametres of breastmilk composition. 
iii. Infantile PCR at birth and four weeks postpartum: To determine the MTCT of HIV. 
iv. Growth velocities of IUGR HIV-infected, HIV-uninfected but exposed and –uninfected 
infants at 6 months: To determine if there was a correction in SGA infants and draw 
associations according to HIV-status/exposure. Associations can be made between 
breastmilk compositon and growth. 
v. Maternal pregnancy weight gain: It was not possible to determine an association 
between a low PI and poor pregnancy weight gain. 




Recommendations to address the research question include: 
i. According to the researchers’ best knowledge, this was the first study that found 
differences in breastmilk composition between HIV-infected and HIV–uninfected 
mothers with premature infants. More studies should be conducted to confirm 
the differences and explore other nutrients that make up the composition of 
preterm breastmilk. 
ii. A full analysis of micronutrients and trace elements in breastmilk samples will 
provide a more complete depiction of differences in nutritive composition. 
iii. A larger subsample of underweight and obese participants should be included to 
adequately investigate the influence of maternal anthropometric parameters on 
that of the infants.  
iv. Although the researchers were able to prove significant differences in breastmilk 
composition among the subsamples, the results could be strengthened with 
larger sample sizes.  
 
Recommendations for further research include the following: 
i. The researchers specifically chose to work with the Ballard score, because 
neonatal nutritional parameters needed to be plotted (and very few women 
have access to an early sonar). However, future studies that investigate 
breastmilk composition only, should rather use birthweight cut-offs.  
ii. Because all mothers included in the study were lodgers and received three meals 
from the hospital’s food service unit, it was assumed that dietary intake was 
comparable for all mothers and therefore dietary intake was not investigated. 
Future studies could take the habitual diets of HIV-infected and HIV–uninfected 
mothers into account. 
iii. Non-nutritive (immunological) factors should be compared between HIV-infected 
and HIV–uninfected mothers with premature infants. Non-nutritive factors may 
also contribute to the macronutrient composition of breastmilk, for example IgA 
and lysozyme, may contribute to total proteins and oligosaccharides may 
contribute to total carbohydrates. 
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iv. Macronutrients: The study found elevation of protein and total fat in preterm 
breastmilk of HIV-infected women. The exact proteins and fatty acids that 
contribute to the elevation should be further explored. Carbohydrates were 
lower in the HIV-infected group. The breakdown of sugars and other 
carbohydrate-containing substrates should be analysed and compared between 
HIV-infected and HIV–uninfected women. 
v. Trace-elements: Copper was elevated and zinc decreased in HIV-infected 
women. Research may invest in the raised anti-oxidant properties of HIV-infected 
breastmilk as well as the copper-zinc interaction. Furthermore, the role of zinc in 
retarded growth of HIV-infected breastfed infants should be explored further. 
vi. Investigations should be conducted to explore the compositional differences with 
respect to nutrients not investigated in this study. 
vii. A high prevalence of IUGR was found in the infant study population. The study 
could not draw conclusive associations between maternal anthropometric 
parameters and ART use; therefore, other medical, maternal and social factors 
should be explored.  
viii. Prospective studies should investigate longterm outcomes such as growth and 
cognitive development of HIV-exposed infants, especially those born with head 
circumference restriction. 
ix. The metabolic programming hypothesis should be explored in this population, in 
other words SGA infants born to mothers at risk of overnutrition. 
x. The micronutrient status of mothers should be explored in relation to breastmilk 
composition and risk of IUGR. 
xi. The role of disease stage in breastmilk composition should be explored. 
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ADDENDUM A: QUESTIONNAIRE  
Demographic Questionnaire  
Participant number  
1. DOB  
 
2. Maternal ethnicity: 
a) African (Black) b) Caucasian (White) 
c) Coloured (Mixed ancestry) d) Asian 
e) Indian f) Other, specify 
 
3. Home (primary) language: 
a) English b) Afrikaans 
c) Xhosa d) Zulu 
e) Tswana f) Southern Sotho 
g) Northern Sotho h) Venda 
i) Tsonga j) Swati 
k) Ndebele  l) Other, specify 
 
 
4. Maternal level of education: 
a) No formal level of education b) Highest grade completed 
c) Tertiary level d) Other (specify) 
 
5. Monthly income: 
a) Number of working adults   
b) Grant(s) (Y/N) and amount  
c) Average monthly income  
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6. Number of people in household: Adults: 
 Children: 
 
7. Age of infant at birth (weeks gestation) :  
8. Parity (including this pregnancy): Para/ 
Gravida 
 
9. Multiparous (Y/N):  
10. Has the mother breastfed an infant 
before? (Y/N) If yes, how many infants? 
 
11. List problems that prevented 
breastfeeding previously OR reasons for 
choosing formula milk. 
 
12. Has the mother given birth to a 
premature infant before? 
 
 
13. HIV status:  
a) HIV-infected receiving HAART (Y/N)  




c) CD4 count  
d) When was last CD4 count taken? 
Date: if available 
i) Before pregnancy of this infant 
ii) During pregnancy of this infant 
iii) After birth of this infant 
e) If no to (a), rapid HIV test result (pos/neg)  
Infant receiving treatment? (Y/N)  
  
 
Stellenbosch University  https://scholar.sun.ac.za
141 
 

























Date: Mark if received 
Breastmilk samples 1:   Sample 1 Sample 2 
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MATERNAL ANTHROPOMETRIC INFORMATION 
Date   
Weight  




If yes, grade? 
 
NEONATAL ANTHROPOMETRIC INFORMATION 
DOB  
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ADDENDUM B: ENGLISH CONSENT FORM 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM   
 
TITLE OF THE RESEARCH PROJECT: 
Breastmilk Composition of HIV-infected Mothers Receiving Anti-retroviral Therapy who 





Carike den Boer 
ADDRESS: 
University of Stellenbosch 
CONTACT NUMBER: 
072 690 6990 (Carike den Boer) 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
study staff any questions about any part of this project that you do not fully understand.  It 
is very important that you are fully satisfied that you clearly understand what this research 
is about and how you could be involved.  Also, your participation is entirely voluntary and 
you are free to say no to participate.  If you say no, this will not affect you negatively in any 
way whatsoever.  You are also free to withdraw from the study at any point, even if you do 
agree to take part. 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and Kalafong Hospital. It will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
Nr: 





What is this research study all about? 
The researcher will ask you if she can look in your hospital file to get information on your 
medical background and your HIV status. All information will be kept confidential and 
private. To get information about your nutritional well-being you will be weighed and your 
height and upper arm circumference will be measured. A translator might be present to 
help the researcher with the procedures. Then, you will be asked to express a little bit of 
your breastmilk into a container. One sample of 30ml each will be taken on the seventh day 
from when you started to produce breastmilk and the other sample (also 30ml) nine days 
from when you started to produce breastmilk. It is anticipated that a total of a 100 mothers 
will participate in the study at Kalafong Hospital. 
What will happen to me if I do take part? 
You will be responsible to give the researchers honest and true information regarding 
yourself and your health. You will be asked to give the researchers one sample of your 
breastmilk on two occasions. You will also be weighed and measured.  
The researcher will also measure your baby’s weight, length and head circumference or get 
it from the hospital file. 
Breastmilk: As part of the study, we want to measure some of the ingredients in your 
breastmilk, such as protein, sugars, fat and minerals.  
These milk samples will be frozen before being tested in the laboratory. The sample will be 
collected in a clean container free of germs.  
Information from your hospital file will be used in the study such as how your baby was 
born, your HIV status and what medications you received during your pregnancy. All 
pregnant women in Gauteng are tested for HIV during pregnancy and because it is 
important for us to know your HIV status, we will get that information from your hospital 
folder. 
Why have you been invited to participate? 
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You have been chosen to take part in the study because you gave birth to a preterm baby 
and are currently breastfeeding or providing breastmilk to your infant.  
What will your responsibilities be? 
You will be responsible to provide the researchers with honest and true information 
regarding yourself and your health. You will be asked to give the researchers two samples of 
your breastmilk. You will also be weighed and measured.  
Will you benefit from taking part in this research? 
You will not directly benefit from participating in this study, but will not be disadvantaged by 
not participating. Your medical care during your hospital stay will not be different from 
other women (who are participating or who are not participating in the study). The results 
of the group as a whole will be published or presented to other healthcare workers, but 
without mentioning your name. Other health care professionals (such as doctors, dietitians 
and nurses) can do further research using the results of this study, that might, in future, 
have benefits for babies who are breastfed.  
 
Are there in risks involved in your taking part in this research? 
No, you are not at risk of any harm. 
Who will have access to your medical records? 
The researcher will have access to your medical records. All information will be kept 
confidential (secret). The results of the group as a whole will be used in an article that will 
be published in a medical journal. Your name will not be used- you will remain anonymous. 
 
The supervisors to the researcher may also have access to the information. This information 
will be kept confidential (secret). 
 
Will my participation in the study be kept confidential? 
Yes, your participation will be kept confidential. The milk samples will be destroyed after the 
study is completed.  The milk samples will be numbered and will not be tracked back to you. 
Only the researcher will know which samples belong to which mother. The researcher will 
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keep all your information strictly confidential and no information will be given about you to 
any person who is not directly associated with this study.  
What will happen in the unlikely event of some form injury occurring as a direct result of your taking 
part in this research study? 
It is unlikely that something will go wrong. If you cannot give the researcher a breastmilk 
sample or stand up to be measured, the researcher will ask you again at a later time. 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study.  There will be no costs involved for you, if 
you do take part. 
Is there anything else that you should know or do? 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by the researcher. 
You can also contact the principal researcher, Carike den Boer, at any time at 072 690 6990 
if you have any questions regarding the study. 
You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled  
Breastmilk Composition of HIV-infected Mothers Receiving Anti-retroviral Therapy who 
Gave Birth To Premature Infants. 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
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 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 








......................................................................   ...................................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
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 I did/did not use a interpreter.  (If a interpreter is used then the interpreter must 
sign the declaration below. 
 
 




......................................................................   ...................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium Tswana. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
Signed at (place) ......................…........…………….. on (date) …………....………………..201 
......................................................................   ...................................................................  
Signature of interpreter Signature of witness 
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ADDENDUM C: TSWANA CONSENT FORM 
 
PAMPIRI TSHEDIMOSETSO YA MOTSAYA KAROLO LE FOROMO YA 
TUMALLANO   
 
SETLHOGO SA POROJEKE YA DIPATLISISO: 
Ditswaki tsa Mekgato ya Bomme ba ba tshwaeditsweng ke mogare wa HIV ba amogela 




Carike den Boer 
ATERESE: 
Karolo ya Kotlo ya Botho, Lephata la Melemo le Saentshe ya Boitekanelo Unibesithi ya 
Pretoria 
012 354 1130 
NOMORO YA MOGALA: 
072 690 6990 
O lalediwa go tsaya karolo mo porojekeng ya patlisiso. Ka kopo tsaya nako go buisa 
tshedimosetso e e tlhagisitsweng fa,eo e tlhalosang dintlha tsa porojeke e. Ka kopo botsa 
badiri ba patlisiso dipotso dingwe le dingwe ka karolo nngwe le nngwe eo o sa e 
tlhaloganyeng sentle. Go botlhokwa thata gore o kgotsofale le go tlhaloganya sentle se 
patlisiso e  e leng ka ga sone le ka fa o ka amegang ka teng. Gape, botsaya karolo ba gago ke 
go ithaopa gotlhelele e bile o letleletswe go se dumele go tsaya karolo. Fa e le gore ga o 
dumele, seno ga se go ame gotlhelele. O letleletswe go ikgogela morago mo patlisisong nako 
nngwe le nngwe, le fa e le gore o ka dumela go tsaya karolo. 
 
Nr: 
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Patlisiso eno e tlhomamisitswe ke Komiti ya “Health Research Ethics” kwa Unibesithi ya 
Stellenbosch le Sepetlele sa Kalafong. E tlile go tsamaisiwa go ya ka ditaelo tsa maitshwaro a 
setho le melawana ya Tumallano ya boditšhabatšhaba ya Helsinki, Ditaelo tsa Aforika Borwa  
tsa “Good Clinical Practice”le “Medical Research Council (MRC) Ethical Guidelines for 
Research”. 
Patlisiso e e ka ga eng? 
Mmatlisisi o tla go kopa tetla ya go leba mo faeleng ya gago ya sepetlele go bona 
tshedimosetso ya letlamorago la boitekanelo ba gago le maemo a gago a HIV. 
Tshedimosetso yotlhe e tla nna sephiri. Go fitlhela tshedimosetso ya boitekanelo kotlo ba 
gago o tlile go kadiwa  bokete jwa mmele, boleele le letsogo godimo la gago. Mofetoledi a 
ka nna teng go thusa mmatlisisi ka tsamaiso. Jaanong, o tla kopiwa go rothetsa bonnye ba 
mekgato mo setshelong. Sampole e le nngwe ya selekano sa 30ml e tlile go tsewa ka letsatsi 
la bosupa go tloga ka nako eo o simolotseng go tswa mekgato fa sampole e engwe (le yone  
ya selekano sa 30ml ) e tla tsewa malatsi a le robong go tloga nako eo o simolotseng go tswa 
mekgato. Go solofetswe  gore paloyotlhe ya bomme ba le lekgolo ba tla tsaya karolo mo 
patlisisong kwa Sepetlele sa Kalafong. 
Go tla diragala eng mo go nna fa e le gore ke tsaya karolo? 
O tlile go nna le maikarabelo a go neela babatlisisi tshedimosetso e e tshepagalang le 
boammaruri ka ga wena le boitekanelo ba gago. O tlile go kopiwa go neela babatlisisi 
sampole e le nngwe ya mekgato mo mabakeng a le mabedi. Gape o tlile go kadiwa le go 
metiwa. 
Mmatlisisi o tla meta le bokete jwa mmele wa lesea la gago, boleele le selekano sa tlhogo 
kgotsa a di tsaya go tswa mo faeleng ya sepetlele. 
Mekgato: Jaaka karolo ya patlisiso, re batla go meta ditswaki dingwe mo mekgatong, tse di 
jaaka poroteine, sukiri, mafura le dimenerale. 
Disampole tseno tsa mekgato di tla tsidifatsiwa pele di diriwa diteko kwa laboratoring. 
Sampole e tla tsewa mo setshelong se se phepa se se tlhokang ditwatsi. 
Tshedimosetso go tswa mo faeleng ya gago ya sepetlele e tlile go dirisiwa mo patlisisong go 
lebilwe ka fao lesea la gago le neng la tsalwa ka teng, maemo a gago a HIV le melemo eo o e 
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fitlhetseng ka nako ya pelego ya gago.Go tla tsewa basadi botlhe ba ba ithweleng mo 
Gauteng diteko tsa HIV ka nako ya pelego ka gonne go botlhokwa mo go rona go itse 
maemo a gago a HIV, re tla fitlhela tshedimosetso eo go tswa mo faeleng ya gago ya 
sepetlele. 
Goreng o laleditswe go tsaya karolo? 
O tlhophilwe go tsaya karolo mo patlisisong ka gonne o tswetse lesea le le tlileng pele ga 
nako e bile gajaana o le anyisa letsele kgotsa o le fepa ka mekgato. 
A maikarabelo a gago e tlile go nna a ma fe? 
O tlile go nna le maikarabelo a go neela babatlisisi tshedimosetso e e tshepagalang le 
boammaruri ka ga wena le boitekanelo jwa gago. O tlile go kopiwa go neela babatlisisi 
disampole di le pedi tsa mekgato ya gago. O tlile go kadiwa le go metiwa. 
A o tlile go ungwa go tsa mo patlisisong eno? 
O ka se ungwe go le kalo mo go tseyeng karolo mo patlisisong eno, fela o ka se kgoreletsege 
ka go se tseye karolo. Tlhokomelo ya boitekanelo ba gago e ka se farologane le ya basadi ba 
bangwe fa o santse o le kwa sepetlele (ba ba tsayang karolo le ba ba sa tseyeng karolo). 
Dipoelo tsa setlhopha sotlhe di tlile go phasaladiwa kgotsa tsa tlhagisiwa kwa badiri ba 
bangwe ba boitekanelo, kwa ntle ga go bua leina la gago. Badiri ba bangwe ba boitekanelo 
(jaaka dingaka, badiri ba manaane a dijo le baoki) ba ka dira patlisiso e e tsweletseng ba 
dirisa dipoelo tsa patlisiso eno, eo  mo isagong, e ka nnang le mosola maleba le masea a a 
fepiwang ka mekgato. 
A o go na le dikotsi tse di leng teng mo go tseyeng karolo ga gago mo patlisisong eno? 
Nyaa, ga go kotsi epe e  e ka go amang. 
Ke mang yo a tlileng go bona direkoto tsa boitekanelo ba gago? 
Mmatlisisi o tla nna le tetla ya go bona direkoto tsa boitekanelo ba gago . Tshedimosetso 
yotlhe e tlile go nna bofitlha (sephiri). Dipoelo tsa setlhopha sotlhe di tlile go dirisiwa mo 
lokwalokgang leo le tlileng go phasaladiwa mo jenaleng ya boitekanelo. Leina la gago le ka 
se dirisiwe-o tlile go nna tlhokaina. 
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Balaodi ba mmatlisisi le bone ba ka nna le tetla ya go bona tshedimosetso. Tshedimosetso 
eno, e tlile go nna bofitlha (sephiri). 
A botsaya karolo ba me bo tlile go nna sephiri mo patlisisong? 
Ee, botsaya karolo ba gago bo tlile go nna sephiri. Disampole tsa mekgato di tlile go nna le 
dinomoro mme seno ga se reye gore o tlile go senolwa. Ke mmatlisisi a le esi yo o tla itseng 
gore ke disampole di fe tse e leng tsa ga mme. Mmatlisisi o tlile go baya tshedimosetso 
yotlhe ya gago sephiri mme ga go tshedimosetso efe e e tla neelwang motho mongwe le 
mongwe yo o sa direng mo patlisisong kgotsa a amega mo go yone. 
 
A go tla diragala eng fa e le gore go nna le tiragalo ya kgobalo e direga ka gonne o tsaya 
karolo mo tshekatshekong ya patlisiso? 
Ga go kgonagalo e e kalo ya gore go ka nna le sengwe se se phoso se se ka diragalang. Fa e 
le gore ga o kgone go neela mmatlisisi sampole ya mekgato kgotsa ga o kgone go emelela 
gore o kadiwe, mmatlisisi o tla go kopa gape mo nakong e e tlang. 
A o tlile go duelwa go tsaya karolo mo patlisisong eno, a go na le ditshenyegelo tse di leng 
teng? 
Nnyaa, o ka se ke wa duelwa go tsaya karolo mo patlisisong . Ga go na dituelo tse di go 
amang, fa e le gore o tsaya karolo. 
A go na le sengwe se o tshwanetsweng ke go se itse kgotsa go se dira? 
O ka ikgolaganya le Komiti ya “Health Research Ethics” mo go 012-938 9207 fa e le gore o na 
le matshwenego kgotsa dingongorego tse di sa tlhagisiwang ke mmatlisisi. 
O ka leletsa le mmatlisisi mogolo, Carike den Boer, nako nngwe le nngwe mo go 072 690 
6990 fa e le gore o na le dipotso maleba le patlisiso. 
O tla fitlhela khopi ya tshedimosetso eno le foromo ya tumallano gore o kgone go di baya 
jaaka rekoto ya gago. 
Maikano a motsaya karolo 
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Ka go saena fa tlase, Nna................................................ ke dumela go tsaya karolo mo 
patlisisong ya setlhogo  
Ditswaki tsa Mekgato ya Bomme ba ba tshwaeditsweng ke mogare wa HIV ba Amogela 




Ke dumela gore: 
 Ke buisitse kgotsa ba mpuiseditse tshedimosetso eno le foromo ya tumallano mme e 
kwadilwe ka puo e ke itseng le go e tlhaloganya. 
 Ke nnile le tšhono ya go botsa dipotso mme di arabilwe sentle tsotlhe. 
 Ke tlhaloganya gore go tsaya karolo ga me mo patlisisong eno go ka boithapo ba me 
e bile ga ka gatelelwa go tsaya karolo. 
 Nka itlhophela go tlogela patlisiso nako nngwe le nngwe mme ka se otlhaiwe le go 
otlhaelelwa pele ka mokgwa mongwe le mongwe. 
 Nka kopa go tlogela patlisiso pele e wetsiwa, fa e le gore ngaka ya tlhatlhobo kgotsa 
mmatlisisi o akanya fa go le maleba go ya ka dikgatlhego tsa me, kgotsa fa e le gore 
ga ke sale morago thulaganyo ya patlisiso, jaaka go dumellanwe. 
E saenetswe kwa (lefelo).........................................ka di(letlha)..........2014. 
 
……………………………………………………   ....................................................... 
Mosaeno wa motsaya karolo   Mosaeno wa Paki 
 
Maikano a mmatlisisi 
 
Nna (leina).............................................ke dumela gore: 
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 Ke tlhalositse tshedimosetso e e mo pampiring go .................................... 
 Ke mo rotloeditse go botsa dipotso le go tsaya nako sentle go di araba. 
 Ke kgotsofetse gore o tlhaloganya sentle dintlha tsotlhe tsa patlisiso, jaaka e 
tlhagisitswe fa godimo. 
 Ke dirisitse / ga ka dirisa mofetoledi. (Fa e le gore mofetoledi o dirisitswe o 
tshwanetse go saena tumallano e e fa tlase). 
 
Saenetswe kwa(lefelo)........................................ka di(letlha)..........................................2014. 
 
................................................................. ..................................................................... 
Mosaeno wa mmatlisisi    Mosaeno wa Paki 
 
Maikano a mofetoledi 
Nna(leina) .............................................................. ke dumela gore: 
 
 Ke thusitse mmatlisisi(leina) ......................................... go tlhalosa tshedimosetso mo 
pampiring eno kwa go (leina la motsaya karolo) ............................................ ke dirisa 
puo ya Setswana. 
 Re mo rotloeditse go botsa dipotso le go tsaya nako sentle go di araba. 
 Ke buile sentle dintlha tse di nepagetseng go ya ka fa di tlhagisitsweng mo go nna. 
 Ke kgotsofetse gore motsaya karolo o tlhaloganya ka botlalo diteng tsa pampiri ya 
tumallano e bile o kgotsofaletse dikarabo tsotlhe tsa dipotso tsa gagwe. 
Saenetswe kwa(lefelo).................................................ka di (letlha)..................................2014. 
 
.............................................................  …………………………………………………………… 
Mosaeno wa mofetoledi     Mosaeno wa Paki 






ADDENDUM D: AFRIKAANS CONSENT FORM 
 
DEELNAME INLIGTINGS PAMFLET EN TOESTEMMINGSVORM 
TITEL VAN DIE NAVORSINGSPROJEK: 
Borsmelksamestelling van HIV Positiwe Moeders wat, Anti-retrovirale Terapie Ontvang Geboorte 





Carike den Boer 
ADRES: 
Navorsingsetiese Komitee, Fakulteit Gesondheidswetenskappe, Universiteit van Pretoria 
012 354 1130 
KONTAKNOMMER: 
072 690 6990 (Carike den Boer) 
U word uitgenooi om aan ‘n navorsingstudie deel te neem. Neem asseblief u tyd om die inligting wat 
die studie beskryf noukeurig deur te lees. Voel vry om die navorsers enige vrae te vra wat onduidelik 
is of wat u nie verstaan nie. Dit is baie belangrik dat u ten volle tevrede is met die voorwaardes en 
dat u die prosedures duidelik verstaan. Wees bewus dat u deelname total vrywillig is en u mag‘nee’ 
sê om deel te neem.. Indien u weier om deel te neem, sal u nie op enige manier negatief beïnvloed 
word nie. U kan ook op enige stadium van die studie besluit om u deelname te stop, al het u 
toestemming gegee om deel te neem. 
Die studie was deur die Gesondheidsnavorsing Etiese Komitee te  Universiteit van Stellenbosch 
goegekeur asook deur Kalafong Hospitaal en sal volgens die etiese riglyne en beginsels van die 
internasionale Deklerasie van Helinski, Suid Afrikaanse Riglyne vir Goeie Praktyk en die Mediese 
Navorsingsraad (MRC) Etiese Riglyne vir Navorsing. 
Waaroor handel die studie? 
Die navorser sal u vra om in u hospitaallêer te kyk om inligting aangaande u mediese geskiedenis en 
u HIV status te kry. Alle inligting sal vetroulik en privaat gehou word.  Om inligting aangaande u 
voedingstatus te kry, sal ons ook u gewig, lengte en middelarmomtrek neem. ’n Vertaler mag 
 
Nr: 
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teenwoordig wees indien dit sou nodig wees. U sal dan gevra word om een monster van u borsmelk 
te voorsien: een monsters van 30ml elk op dag 7 vandat u begin borsmelk produseer het en een 
monster (ook 30ml elk) op dag 9 vandat u begin borsmelk produseer het. Daar word verwag dat daar 
in total ‘n 100 moeders aan die studie sal deelneem by Kalafong Hospitaal. 
Wat sal gebeur indien ek besluit om deel te neem? 
U sal verantwoordelik wees om vir die navoring eerlike en akkurate inligting aangaande uself, u 
gesondheid en u dieet te gee. U sal ook gevra word om twee borsmelkmonsters te gee en om 
geweeg en gemeet te word.  
Die navorser sal ook u baba se gewig, lengte en kopomtrek neem of die inligting uit die hospitaallêer 
kry. 
Borsmelk: Deel van die studie studie behels dat ons sekere bestanddele van u borsmelk soos die 
proteїen-, suiker-, vet- en mineraalinhoud, meet. Ons sal op dag 7 en dag 8  vandat u begin borsmelk 
produseer het u vra om ‘n borsmelkmonster vir ons te gee. 
Hierdie melkmonsters sal gevries word en dan in ‘n labratorium getoets word. Die monster sal in 
steriele (kiemvrye) houers gehou word. 
Inligting aangaande u hospitallêer sal in die studie gebuik word. Dit sluit in hoe u baba gebore is, u 
HIV status en die medikasie wat u gedurende u swangerskap ontvang het in. Alle swanger vroue in 
Gauteng word vir HIV getoets. Omdat dit vir ons belangrik is om u HIV status te weet, sal ons dit in u 
hispitaallêer kry. 
Hoekom is u uitgenooi om deel te neem? 
U is gekies om deel te neem, omdat u aan preterm baba geboorte gegee het en op die oomblik 
borsvoed of borsmelk aan u baba verskaf. 
Wat sal u verantwoordelikhede wees? 
U sal verantwoordelik wees om eerlike en akkurate inligting aan die navorser aangaande u self en u 
gesondheid te voorsien. Verder sal die navorser van u verwag om twee monsters van u borsmelk te 
voorsien asook om geweeg en gemeet te word. 
Sal u bevoordeel word deur u deelname? 
U sal nie direk bevoordeel word deur deel te neem nie, maar u sal ook nie benadeel word deur te 
weier om deel te neem nie. U mediese sorg tydens u verblyf in die hospital sal nie van ander vroue 
wat nie aan die studie deelneem verskil nie. Die resultate van die groep as geheel sal gepubliseer of 
voorgedra word. Ander professionele gesondheidswerkers (soos dokters, dieetkundiges en 
verpleegsters) kan die resultate van hierdie studie gebruik om verdere navorsing te doen wat in die 
toekoms voordele vir babas wat geborsvoed word mag inhou. 
Is daar enige risiko’s indien ek belsuit om deel te neem in die studie? 
Nee, u het nie ‘n risiko om skade te ly nie.  
Wie sal toegang tot my mediese rekords hê? 
Die navorser sal toegang tot u mediese rekords hê. Alle inligting sal vetroulik (geheim) gehou word. 
Die resultate van die groep as geheel sal in ‘n artikel gebruik word wat in ‘n mediese joernaal 
gepubliseer sal word. U naam sal nie gebruik word nie - u sal anoniem bly.  
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Die navorser se toesighouers sal toegang tot die inligting verkry. Die inligting wat hulle sien sal 
konfidensieel (geheim) gehou word en hulle sal nie verdure toegang tot hierdie inligting verkry nie. 
 
Sal my deelname in die studie vetroulik gehou word? 
Ja, u deelname sal vertroulik gehou word die borsmelkmonsters sal vir analise en gevolgtrekking 
gehou word en dan weggegooi word wanneer die studie verby is. Die monsters sal genommer word 
en kan nie terug na u toe gelei word nie. Slegs die navorser sal weet watter monsters aan watter 
moeder behoort. Die navorser sal alle inligting streng vertroulik hou en geen inligting sal oor u 
bekend gemaak word deur iemand wat nie direk by die studie betrokke is nie. 
Wat sal gebeur in die onwaarskynlikheid dat u ‘n vorm van besering opdoen as ‘n direkte gevolg 
van u deelname in die studie? 
Dit is baie onwaarskynlik dat iets sal verkeerd gaan. Indien u nie ‘n borsmelkmonster kan voorsien of 
beweeglik is teen die tyd wat die navorser u daarvoor vra nie, kan u dit op ‘n latere stadium doen. 
Wat sal u betaal word om deel te neem in die studie en is daar enige kostes betrokke? 
Nee, u sal nie vergoed word om in die studie deel te neem nie. U sal ook geen geldelike uitgawes he 
nie. Is daar enige iets anders wat u moet weet? 
U kan die Gesondheidswettenskappe Navorsingskomitee by 021-938 9207 bel indien u navrae of 
klagtes het wat nie voldoende deur die navorser kan beantwoord word nie. 
U kan die hoofnavorser, Carike den Boer, ter enige tyd by 072 690 6990 skakel indien u vrae oor die 
studie het. 
U sal ‘n kopie van hierdie inligting en toestemmingsvorm vir u eie rekords ontvang. 
 
Verklaring deur die deelnemer: 
Deur hieronder te teken, gee ek …………………………………..…………. toestemming om in die studie deel 
te neem: Premature Borsmelksamestelling van HIV Positiewe Moeders Wat Anti-retrovirale Terapie 
Ontvang en Geboorte geskenk het Aan Premature Babas. 
Ek verklaar dat: 
 Ek die inligting en toestemmingsvorm gelees het of iemand dit vir my gelees het en dat dit in 
‘n taal is waarin ek vlot en gemalklik is. 
 Ek was ‘n kans gegun om vrae te vra en dit was voldoende beantwoord. 
 Ek verstaan dat my deelname vrywillig is en ek voel nie gedruk om deel te neem nie. 
 Ek mag deelname staak op enige stadium en sal nie gepenilariseer word om so te doen 
nie. 
 Ek mag gevra word om die studie te verlaat voordat dit voltooi is indien die dokter of 
navorser voel dit nie in my beste belange is nie of as ek nie die studieplan, soos 
ooreengekom, volg nie. 
 










 ............................................................................  .........................................................................  
Handtekening van deelnemer Handtekening van getuie 
 
 
Verklaring deur die navorser 
Ek (naam) ……………………………………………..……… verklaar dat: 
 
 Ek die dokument aan ………………………………….. verduidelik het. 
 Ek haar aangemoedig het om vrae te vra en die tyd gemeen het om dit te beantwoord. 
 Ek is tevrede dat sy alle aspekte van die navorsingstudi ten volle verstaan soos hierbo 
uiteengesit is. 
 Ek het/ het nie ‘n vertaler gebruik nie. (Indien ‘n vertaler gebruik is, moet die vertaler 
die verklaring hieronder onderteken.) 
 




 ............................................................................  .........................................................................  
Handtekening van deelnemer     Handtekening van getuie 
 
Verklaring deur vertaler: 
 
Ek (naam) ……………………………………………..……… verklaar dat: 
 
 Ek in die navorser (naam) ………………………………………. gehelp het om die inligting in 
hierdie document aan (naam van deelnemer) te verduidelik in die taal Tswana. 
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 Ons het haar aangemoedig het om vrae te vra en die tyd gemeen het om dit te 
beantwoord. 
 Ek het dit on ‘n feitelike korrekte weergawe oorgedra soos wat dit aan my oorgedra 
was/ 
 Ek is tevrede dat die deelnemer die inhoud van hierdie toestemmingsdokument 
verstaan en dat al haar vrae voldoende beantwoord is. 
 
 




 ............................................................................  .........................................................................  
Hantekening van vertaler Handtekening van getuie 




ADDENDUM E: MUAC PERCENTILES 
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ADDENDUM F: FENTON GROWTH CHART 
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